US20050203444A1 - Ultrasound therapeutic device - Google Patents

Ultrasound therapeutic device Download PDF

Info

Publication number
US20050203444A1
US20050203444A1 US11/066,102 US6610205A US2005203444A1 US 20050203444 A1 US20050203444 A1 US 20050203444A1 US 6610205 A US6610205 A US 6610205A US 2005203444 A1 US2005203444 A1 US 2005203444A1
Authority
US
United States
Prior art keywords
treatment
ultrasound
treatment head
controller
head
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/066,102
Inventor
Klaus Schonenberger
Felix Buhlmann
Pierre-Yves Muller
Pierre Rigaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compex Medical SA
Original Assignee
Compex Medical SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compex Medical SA filed Critical Compex Medical SA
Priority to US11/066,102 priority Critical patent/US20050203444A1/en
Publication of US20050203444A1 publication Critical patent/US20050203444A1/en
Assigned to BANK OF AMERICA, N.A., AS COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS COLLATERAL AGENT SECURITY AGREEMENT Assignors: ENCORE MEDICAL FINANCE LLC, ENCORE MEDICAL HOLDINGS LLC
Assigned to ENCORE MEDICAL ASSET CORPORATION reassignment ENCORE MEDICAL ASSET CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Assigned to COMPEX MEDICAL S.A. reassignment COMPEX MEDICAL S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BUHLMANN, FELIX, MULLER, PIERRE-YVES, RIGAUX, PIERRE, SCHONENBERGER, KLAUS
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/44Constructional features of the ultrasonic, sonic or infrasonic diagnostic device
    • A61B8/4438Means for identifying the diagnostic device, e.g. barcodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017Electrical control of surgical instruments
    • A61B2017/00199Electrical control of surgical instruments with a console, e.g. a control panel with a display
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N2007/0004Applications of ultrasound therapy
    • A61N2007/0008Destruction of fat cells

Definitions

  • the present invention generally relates to the field of ultrasound treatment. More specifically, the present invention relates to an ultrasound therapeutic device capable of automatically determining a considerate treatment dose, controlling acoustic power output efficiency, and performing adjustable calibration functions.
  • Therapeutic ultrasound devices have long been utilized in the treatment of musculoskeletal and tissue injuries. Greater understanding of ultrasound, and the application of ultrasound to human skin and tissue, have expanded the scope of possible uses for these devices. For instance, in addition to the thermal or vibratory focus of more traditional devices, developments have been made in which ultrasound devices can be directed toward introducing various drugs into the human body through the skin. However, the increase in potential uses and advantages for these therapeutic ultrasound devices has come at a price. Namely, advancements in the technology and the understanding of the potential applications, has correspondingly led to the complication of setup procedures, inefficient power adjustments, and the need for more precise calibration procedures.
  • Ultrasonic therapy devices impose mechanical vibrations on tissue and skin to cause various thermal and non-thermal effects.
  • An ultrasound generator outputs electric power to a treatment head.
  • the treatment head includes a transducer which converts the power from the generator into ultrasonic energy or acoustic power. It is this acoustic power that is transmitted for therapeutic treatment through the patient's tissue.
  • the requisite acoustic power can vary greatly depending on the treatment goals, the target tissue type, the target tissue depth, and other like factors.
  • the duration of the ultrasonic treatment dosage to the patient is important. Treatment goals, the unique characteristics of the target tissue, and like considerations dictate the treatment duration.
  • the unique and specific characteristics of the target tissue, and the nature and thickness of intermediate tissue and/or the target tissue, are requisite factors to be considered in determining a proper ultrasound treatment dose. This is true since both the thermal and non-thermal effects of ultrasound are dependent upon these factors. Despite the fundamental importance of these considerations, conventional ultrasound therapeutic devices simply have not advanced methods and apparatus that properly consider and process known histological tissue characteristics in generating a treatment dose.
  • U.S. Pat. No. 5,413,550 (“the '550 Patent”) discloses an attempt to provide for considerate dose control.
  • the '550 Patent is directed to an ultrasound device including a controller programmed to calculate a treatment dose.
  • the treatment dose consists of treatment frequency, output intensity, and treatment time.
  • the programmed controller determines and generates the dosage parameters based on the inputting of numerous treatment parameters by the end user.
  • the device requires values for the following primary treatment parameters in order to calculate a dosage: depth of tissue to be treated, the desired tissue temperature rise, the tissue area to be treated, and the selection of an ultrasound couplant.
  • the user may input the tissue type, and a duty factor value as secondary parameters.
  • the device of the '550 patent performs routine checks to determine if treatment parameters have been entered.
  • the controller circuitry inserts a default value in place of the missing parameter(s). As a result, it is possible to enter only one of the primary treatment parameters, with each of the remaining parameters being substituted for default values. Such a default-driven device and process is problematic and fails to properly focus the ultrasound treatment on ultrasound effects and histological tissue data.
  • U.S. Pat. No. 4,368,410 discloses an ultrasound therapy device wherein an optimal electric output power level is inputted into the device. Feedback signals from a driver circuit proportional to the transducer voltage and current are returned to an analog servo circuit and a voltage representing true electric power is calculated. If the output power represented by the voltage level increases then it is an indication that there is a reduction in the load on the transducer, and the drive signal is decreased. Similarly, if the instant voltage decreases, an increase in the signal is initiated to compensate for an increase in the load on the transducer.
  • the innate problem with such a system is that while it does acknowledge the effects varying treatment techniques, treatment zones, and an individuals body can have on ultrasound treatment, it does not properly use this information in providing for a truly responsive individualized treatment dosage. Focus is on maintaining a constant electric power output and not on performing acoustic analysis. Events and circumstances effecting the ultrasound treatment are not properly considered—i.e, the introduction of intermediate tissue, the natural changes across a patient's body “zones”, and the like.
  • Each treatment head of an ultrasound therapeutic device requires calibration. Primarily, this calibration is needed in order to accommodate and adjust for various innate properties and characteristics unique to particular heads.
  • the head must be properly calibrated in order to correctly match the specific resonance frequencies of its constituent ceramic. For instance, each ceramic treatment head varies in its material properties.
  • proper operation and acoustic output for each and every head mandates at least an initial head calibration.
  • this calibration is done in the factory prior to receipt of the device by the end user. In many cases, this is the only calibration allowed for, and any later re-calibration must again occur at the factory.
  • these factory calibrations are problematic since untimely degeneration can adversely affect treatment quality and effectiveness.
  • the ultrasound therapeutic system and methods in accordance with the present invention substantially solve the problems and weaknesses present in the prior art devices and methods.
  • the present invention is generally directed to an ultrasound treatment system wherein it is preferred that each of the described prior art deficiencies are addressed in one device.
  • the ultrasound device and methods of the present invention are directed to providing an optimal initial treatment dose based on complete processing of user-inputted histological tissue data, employing an automatic regulatory feedback loop to maintain optimal acoustic power output to the patient during operation, and providing a simple yet efficient user-initiated treatment head calibration technique.
  • the treatment system of the present invention includes multi-mode treatment techniques/effects, and user-specific memorization functions.
  • the ultrasound therapeutic system of the present invention generally includes a generator unit, at least one transducer treatment head, and a programmable controller.
  • the generator is in operable communication with the at least one transducer treatment head such that electric power outputted from the generator to the head is converted into acoustic power by the head.
  • Re-programmable software at the controller generally controls all features and functions for the system.
  • the controller calculates an initial optimal treatment dose, maintains effective acoustic power transmitted to the patient through the at least one treatment head, performs calibration procedures for the at least one treatment head, controls outputting for each supported treatment mode, and provides for various other features and functions as will be discussed in further detail herein.
  • the present invention is directed to intelligent and simplified automatic dosage determination.
  • the output dose is calculated by processing values inputted by the user for target tissue type, intermediate tissue type, and tissue depth/thickness.
  • the present invention does not import or process arbitrary default values for treatment couplant, tissue configuration, and the like. Instead, dosage is based on the fundamental tissue data inputted, wherein the controller performs simulation comparisons to derive the smallest dosage needed to optimally achieve the therapeutic treatment effect.
  • the dosage determination of the present invention through processing of the inputted histological tissue data, takes into account the relevant tissue layer structure to adjust for the effects caused by innate losses through tissue absorption and reflections caused by impedance discontinuities between different tissue layers. Wave reflection and absorption characteristics are dynamically considered in order to properly understand the resulting output that will be delivered to the target tissue of the patient in light of the relevant tissue structure.
  • the feedback loop of the present invention is also considerate in its function. Rather than seeking to maintain a constant electrical output, as is often practiced in conventional devices, the ultrasound device of the present invention controls and monitors the effects of the treatment on the transducer head to maintain a constant ideal acoustic power. As a result, changes that may occur naturally during treatment, such as changes caused by the innate acoustic properties of the tissues proximate the treatment head, are properly considered.
  • the present invention includes an automatic calibration feature. This feature enables new and replacement treatment heads to be introduced without having to send the entire device away for calibration.
  • the ultrasound device of the present invention automatically determines the complex impedance of the transducer head, after calibration, and maintains acoustic power even in the presence of changes in the real or imaginary portion of the acoustic impedance of the relevant tissue.
  • FIG. 1 is a front view of an embodiment of an ultrasound therapeutic device in accordance with the present invention.
  • FIG. 2 a is a diagram demonstrating ultrasonic beam absorption and reflection losses resulting from a specific human tissue structure.
  • FIG. 2 b is a block diagram of the operation of thermal dosage control in accordance with an embodiment of the present invention.
  • FIG. 3 is a diagram plotting the frequency versus conductance of a transducer in accordance with an embodiment of the present invention.
  • FIG. 4 a is a diagram of transducer circuitry in accordance with an embodiment of the present invention.
  • FIG. 4 b is a diagram of transducer circuitry in accordance with an embodiment of the present invention.
  • FIG. 5 is a block diagram of the ultrasound system in accordance with an embodiment of the present invention.
  • FIG. 6 is a diagram depicting the real and imaginary components of measured voltage and current in accordance with an embodiment of the present invention.
  • the ultrasound system 10 generally includes a device housing 12 , a generator/output stage high frequency amplifier 14 , at least one transducer treatment head 16 , and a programmable controller 18 .
  • the generator 14 and controller 18 are housed within the device housing 12 , and are both in operable communication with the transducer 6 via a frequency cable 20 .
  • the generator 14 is an electric power source commonly understood by one skilled in the art. For instance, a 48 Volt dc, 0.85 Amp main power source can be utilized in one embodiment, while others could implement similar compatible units.
  • First and second working frequencies of the generator 14 are preferably approximately 1.017 MHz and 3.2 MHz, respectively. It is possible to have a measurable tolerance/deviation of +/ ⁇ 30 KHz on the first frequency and +/ ⁇ 50 KHz on the second frequency. Other output frequencies and permissible frequency tolerances understood to one skilled in the art are also envisioned.
  • the electric power frequency outputs are outputted from the generator 14 to the transducer head 16 through the frequency cable 20 .
  • the at least one transducer treatment head 16 is a transducer head of a predetermined size, with the head 16 generally including a handling portion 26 , a transducer element 28 , and a treatment surface 30 .
  • Each treatment head 16 utilized for the present invention is preferably watertight for optimal use even if completely submerged.
  • Various embodiments can employ different sized treatment heads 16 . For instance, ultrasound treatment needs and human body structure and size for a specific focus treatment region on an individual can influence the size of the treatment head. Generally, a large and small head will be interchangeable using the same frequency cable 20 .
  • the ultrasonic transducer element 28 of the treatment head 16 is typically constructed of a ceramic (piezo) material.
  • the element 28 will have a maximum output of acoustic power substantially at its resonance frequency.
  • the treatment head 16 will require initial and, perhaps, periodic self-calibration to guarantee that this optimal resonance frequency for the respective transmission element 28 is obtained and maintained. While various treatment heads 16 can be exchanged to meet specific ultrasonic treatment requirements, there is no need to switch out the cable 20 .
  • Conventional devices utilize a unique cable for each treatment head, a practice that can be quite costly, and that can make transportation and storage cumbersome and inconvenient. As discussed herein in describing the cable 20 , the present invention eliminates this innate drawback found in conventional devices.
  • the treatment head 16 further includes a configuration monitoring chip to measure, observe and store data. For instance, operation temperature at the head 16 , head 16 serial numbers, head size, calibration data, and a myriad of other information can be stored such that the controller 18 in operable communication with the head 16 can store data to, and retrieve data from, the head 16 .
  • This storage and reprogramming can be accomplished with the use of EEPROM, or other non-volatile memory and storage technologies. For instance, a Dallas DS-1820 chip (manufactured and sold by Dallas Semiconductor of Dallas Texas), or other chips capable of performing these storage and monitoring functions can be utilized without deviating from the spirit and scope of the present invention.
  • the frequency cable 20 shown in FIG. 1 generally includes at least one set of end connectors 34 and 35 sized and shaped for connecting to respective system 10 components.
  • at least one end connector 35 can be removably connected to the generator 14 at the housing 12 and the distal end connector 34 of the same cable 20 can be removably connected to the transducer treatment head 16 .
  • various treatment heads 16 can be exchanged for operable use with the one common cable 20 .
  • This unique swap/exchange feature is possible due to the selectively engageable distal end connector 34 .
  • a fixed and head-specific cable is avoided such that the present invention promotes interchangeability and treatment flexibility, while at the same time promoting storage and transportation.
  • Each of the end connectors 34 and 35 is generally combined or connected to a system component via a socket or plug connection to facilitate maintenance, selective replacement, and adjustable configuration, with each connection preferably being watertight.
  • the controller 18 includes a microprocessor 36 and control circuitry for providing re-programmable software and hardware control of the present invention.
  • the microprocessor 36 is programmed to receive input and execute control software/algorithms in accordance with predetermined and inputted data.
  • the microprocessor 36 is housed within the housing 12 and is in operable communication with the generator/output stage high frequency amplifier 14 , treatment head 16 , and each of the other components directly and/or through the controller 18 .
  • flash ROM, EEPROM, non-voltaile memory, and RAM can be employed in conjunction with the microprocessor 36 at the controller 18 for data storage and retrieval.
  • the housing 12 generally includes a data input portion 38 and a display portion 40 .
  • the input portion 38 can comprise input keys or other known input devices for receiving data inputted by an end user in response to prompting from the display portion 40 or from volitional decisions to pursue known treatment goals and program routines.
  • the data input portion 38 and display portion 40 are in operable communication with the controller 18 .
  • the system 10 of the present invention can prompt the end user to input specific individualized treatment data, wherein the controller 18 can utilize the data to calculate and initiate ultrasound treatment, and provide responsive output and interface adjustments during treatment.
  • a treatment session or use of the system 10 will involve the following series of inputs, outputs, and automatic adjustments.
  • a treatment “type” must be inputted into the system 10 via prompting on the display portion 40 .
  • Thermal allows the end user or patient to receive a thermal energy effect from the treatment head 16 at the treatment surface 30 .
  • a treatment selection initiates a specific device configuration at the controller 18 wherein the ultrasound energy transmission is converted into thermal energy.
  • Such a conversion leads to a local temperature elevation which particularly effects deeper dense tissue of the patient.
  • the proper ultrasound transmission is highly dependent upon inputted histological data from the patient/end user.
  • the selection of a biological treatment type is directed to a pulsed ultrasound output mode wherein the pulse causes the oscillation of molecules accompanied by marked pressure variations.
  • this oscillation can lead to the formation of micro-bubbles by cavitation, which in turn can produce a beneficial micro-traumatic stress in indurated tissues, inflammatory foci, local calcified accumulations, and the like.
  • a phonophoresis treatment type permits the patient to take advantage of the increased skin permeability that accompanies ultrasound waves. Radiation pressure at the skin due to the inherent permeability increase promotes penetration of medicines through the epidermis layer of the patient. With this treatment selection, there is generally no need for the patient to input histological data or treatment parameters since ideal penetration of the substance is predetermined to facilitate performance and efficiency.
  • a manual setting is selectable so that the patient can control each of the relevant microprocessor-controlled treatment parameters—intensity, duration, frequency, and emission mode.
  • these treatment parameters are calculated and adjusted automatically by the controller 18 implementing software algorithms running on the microprocessor 36 .
  • histological structure data for the individual patient is needed.
  • This histological data generally comprises the target tissue type (tissue to be treated), and the intermediate tissue type and depth (subcutaneous tissue, if any, between the device and the target tissue).
  • target tissue type tissue to be treated
  • intermediate tissue type and depth subcutaneous tissue, if any, between the device and the target tissue.
  • Accurate calculation and inputting of this limited histological data will provide the microprocessor 36 with enough information to provide for a highly controlled and efficient treatment of the patient.
  • the necessary treatment parameters and treatment dosage can be selectively and effectively controlled having only this histological data from the patient/user.
  • the target tissue is generally selected at the input 38 panel of the system 10 from a programmable list.
  • This list can comprise bone, muscle, fat, aponeurosis, tendon, or other targets known to one skilled in the art.
  • the target tissue will be the only inputted/selected histological data. For instance, if the target tissue is fat, there may not be an intermediate tissue to take into account in controlling the ultrasound treatment to the patient. As such, only the depth of the fat target tissue will need to be inputted.
  • the effect of relevant intermediate tissue must be accounted for in determining a treatment dosage.
  • the target tissue selection may be muscle.
  • the intermediate tissue depth can be measured with the use of skinfold pinch calipers, estimated on the basis of the physician's or therapist's knowledge of human anatomy (i.e., palpatory anatomy), and the like.
  • the microprocessor 36 can take the inputted histological data alone and determine the proper intensity, duration, frequency, and emission mode.
  • the treatment session Upon the inputting of user selections and the computed parameter settings and feedback controls, the treatment session will begin by applying the treatment head to the target location on the patient.
  • the treatment head 16 output dosage is controlled by the controller 18 . If at any time the head 16 is removed from the patient during the designated treatment period, for a predefined period of time, the controller 18 will initiate a shut down procedure to stop output from the generator 14 to the treatment head 16 .
  • the algorithmic simulation functions of the microprocessor 36 automatically calculate and control the treatment dosage to create a tissue temperature elevation based on the relevant histological data.
  • the intensity and duration parameters are fully correlated.
  • a change either manually or automatically, will cause the microprocessor 36 software to automatically change the remaining value correspondingly such that the product of the at least two values remains substantially unchanged.
  • the product of intensity and duration is generally used to produce a target tissue temperature elevation of 7 degrees Celsius.
  • a continuous transmission (1/1), rather than pulsed, is typically initiated by the software in thermal mode since such a transmission promotes the desired tissue temperature elevation.
  • This product of acoustic intensity and treatment duration is the treatment dosage.
  • the dosage is a function of the losses from absorption of the ultrasound beam as it travels through relevant tissues and the losses from reflections at the interfaces between adjacent tissues having different acoustic impedances.
  • the quantity of ultrasound which ultimately reaches the target tissue is the therapeutically effective energy which participates in the local elevation of tissue temperature. Since the temperature elevation depends on dosage, the user can change the remaining treatment duration or the intensity at anytime.
  • the software selects the frequency of the output signal based on the histological data inputted. Specifically, the target depth and intermediate tissue dictate the level of penetration required to provide an effective therapeutic dose. In one embodiment, a frequency of approximately 1 MHz is utilized to penetrate relatively deep tissue since such a signal will be less absorbed by the tissue. Conversely, a frequency of approximately 3 MHz is utilized to penetrate relatively shallow tissue. Preferably, the microprocessor 36 software performs simulations at both the 1 MHz and 3 MHz levels to determine which signal will require the smallest dosage while still obtaining the requisite therapeutic effect. Other predetermined or variable frequency determinations can be made as well without deviating from the spirit and scope of the present invention.
  • the user is required to enter specific data at an initial input stage 50 .
  • the user is first prompted to enter a target tissue type.
  • a target tissue type Generally, fat, muscle, tendon, and bone are the tissue types available for selection or input.
  • the user is prompted to input the depth of the tissue between the target and the treatment head 16 . It is preferred that this depth be entered in centimeters, but other measurements are also envisioned. For instance, if the target tissue inputted is tendon, it is possible that there is muscle and/or fat intermediate the tendon. As discussed, this tissue intermediate the target tissue must be considered before calculating a truly effective treatment dosage.
  • Tissue depth and thickness calculations can be performed using techniques known to one skilled in the art. For instance, pinch calipers and the physician's or therapist's knowledge of the human anatomy can be employed. Depending on the presence of intermediate fat or muscle, and the corresponding depth for the intermediate tissue, the microprocessor 36 software will process the data at an intensity transmission stage 52 .
  • This reflection coefficient depends on the acoustic impedance of layer i (Z i ) and layer j (Z j ):
  • R i ⁇ ⁇ j ( z i - z j ) 2 ( z i + z j ) 2
  • tissue impedance levels for bone, skin, tendon, muscle, and fat are known and processed depending on the referenced tissue inputs such that each impedance value corresponds to a wave reflection at the interface of adjacent tissues.
  • a ⁇ value representing the influence of the reflection characteristics of interfacing fat and tendon tissue ( ⁇ ft ) will equate to a coefficient of 0.934, which represents a 93.4% transmission intensity and a 6.6% loss due to reflections at the interface.
  • ⁇ mt 0.974
  • ⁇ st 0.968
  • ⁇ sb 0.748
  • ⁇ fb 0.685
  • ⁇ mb 0.761
  • ⁇ fm 0.990
  • ⁇ fs 0.990
  • ⁇ sm 0. 890
  • a beam attenuation
  • absorption
  • d beam diffusion or scattering
  • the appropriate ultrasound frequency intensity (I 0 ) and treatment duration (T) are calculated such that the product of the intensity and the treatment duration equals the treatment radiation dosage D.
  • an ideal frequency must be calculated.
  • This ideal frequency for the ultrasound intensity I 0 is based on a simulation run for at least two frequencies—1 MHz and 3 MHz. It should be noted that these frequencies, while preferred, are not in any way exhaustive in nature. For instance, other frequency ranges and values can be utilized depending on the particular desired therapeutic effect. In addition, values such as 1 MHz and 3 MHz are obviously rounded for ease of explanation an 9 d calculation.
  • the frequency intensities can be assigned as 1.017 MHz ⁇ 30 KHz, and 3.2 MHz ⁇ 50 KHz. Other values and corresponding ranges are also envisioned.
  • T is the treatment duration (i.e., seconds)
  • C v is a thermal coefficient (heat capacity per unit volume)
  • a is the attenuation coefficient
  • again represents consideration of the effects of the actual tissue layer structure in an intensity transmission coefficient.
  • the attenuation coefficient a represents absorption within the tissue layer of a level of energy lost in the form of heat. Variable attenuation coefficient values known to one skilled in the art as being representative of these tissue-specific heat absorption effects can be employed without deviating from the spirit and scope of the present invention.
  • a product A is assigned the resulting dosage product for 1 MHz
  • B is assigned the dosage product for 3 MHz.
  • the products A and B are compared and analyzed to determine the smallest dose D that can be employed while still reaching the desired therapeutic effect based on known histological data from the user.
  • a value of 3 MHz is assigned as the output frequency
  • a value of 1 MHz is assigned.
  • intensity and treatment duration end points are examined based on the simulation results to determine optimum values for generating the product dosage, wherein the resulting product dosage is processed to determine whether it falls within an acceptable range defined by predetermined minimum and maximum product dosage values.
  • These values can be a minimum dosage value of 6 Ws/cm 2 (Watt seconds per square centimeter) and a maximum value of 5400 Ws/cm 2 .
  • a maximum product dosage of 5400 is calculated based on the above simulation equations, then a set intensity I 0 , is assigned to approximately 3 W/cm 2 , with a corresponding treatment duration of approximately 1800 seconds.
  • the microprocessor 36 can downsize the dosage if it exceeds the maximum, up the dosage if it equates to a value below the acceptable minimum level, and can process variable levels between these end point values.
  • This equation links the variables such that a change in one variable can cause the microprocessor 36 program to correspondingly change the other variables to produce a constant dosage.
  • the algorithmic simulation functions of the microprocessor 36 take tissue configuration into account and automatically select the treatment parameters that will produce the required mechanical effect and minimize tissue temperature elevation. Whereas a tissue temperature elevation is the desired effect in the thermal treatment mode, a thermal effect is not beneficial and must be minimized in biological mode in favor of a mechanical effect.
  • the software automatically determines the intensity, frequency, emission mode and duration of treatment needed in biological mode. In one embodiment, these values are obtained from a look-up table.
  • the desired mechanical effects of biological mode are typically induced using a pulsed emission mode with different duty cycles.
  • the ultrasonic pressure waves produce an oscillation of molecules in the target tissue. This oscillation creates microscopic bubbles called cavitation bubbles that generate small shockwaves in the tissue when they collapse. These small shockwaves induce microscopic mechanical effects in the tissues that enhance the healing process by causing the tissues to grow stronger in reaction to the micro-traumatic stress effect.
  • Biological mode is typically beneficial to indurated tissues, inflamed areas, local calcifications, accumulations of blood such as hematomas, bruises and blood clots, and areas of fibrosis.
  • phonophoresis mode ultrasound is employed to aid in the penetration of drugs through the skin and into target tissue.
  • Phonophroesis mode enhances local application of a drug by increasing the permeability of the skin and exerting a radiation pressure that promotes the penetration of drugs deep into tissues.
  • the ultrasound generator 14 includes a novel feedback loop feature that operates to maintain the delivery of acoustic power at a constant level.
  • a simplified block diagram 100 of the feedback loop in accordance with the present invention is shown in FIG. 5 .
  • the feedback loop operates to measure a coupling efficiency between the transducer treatment head 16 and the biological tissue of the patient.
  • the coupling efficiency is a ratio of the acoustic power effectively transmitted into the patient to the electric power delivered to the transducer treatment head 16 from the generator 14 .
  • the coupling efficiency is dependent on patient tissue configuration as tissue impedance varies with tissue type.
  • the tissue in contact with the transducer treatment head 16 is soft, i.e., skin with a thick layer of fat, the acoustic impedance will be low and the coupling efficiency will be low. If the tissue is instead skin with a thin layer of fat and a large bone near the skin surface, the coupling efficiency will be higher.
  • the microprocessor 36 adjusts the electric power, P e , such that the effective acoustic power transmitted to the patient is maintained constant regardless of the tissue type encountered. While the coupling efficiency, ⁇ , can be expressed by the above equation, the microprocessor 36 uses a modified equation to calculate ⁇ and determine the transducer efficiency for the purpose of adjusting the electric power to maintain the acoustic power.
  • FIG. 4 a depicts an equivalent circuit 88 of the piezo transducer close to its resonant frequency in accordance with the present invention.
  • internal mechanical losses are represented by R i 92
  • R r 90 represents the radiation resistance.
  • the acoustic power emitted can be viewed as the power dissipated across the radiation resistance, R r 90 .
  • R s represents the sum of R i 92 and R r 90
  • the value of R s can be obtained by measuring the overall admittance (the reciprocal of the overall impedance) of the equivalent circuit at resonant frequency.
  • C s 74 and L s 76 resonate together and further reduce the equivalent circuit 88 to the circuit 78 depicted in FIG. 4 b .
  • FIG. 3 is a diagram plotting the frequency 72 versus conductance 70 of a transducer 16 in accordance with the present invention.
  • R s the value of the admittance
  • G max 84 the maximum value of the real portion of the admittance
  • f s 86 the series resonant frequency
  • the effective radiation resistance R r 90 actually represents the transmission of ultrasonic energy out of the transducer.
  • G 0 the series conductance of the unloaded transducer treatment head 16 .
  • FIG. 5 represents a block diagram of the ultrasound system in accordance with an embodiment of the present invention.
  • the analog multiplier 94 receives a measured voltage signal 96 and a measured current signal 98 from the generator/output stage high frequency amplifier 14 .
  • the analog multiplier 94 is also connected to a 90-degree quadrature signal generator 104 .
  • the 90-degree quadrature signal generator 104 receives a reference sine wave 110 from the digital sine wave generator 112 and in turn provides the analog multiplier 94 with sine 106 and cosine 108 reference signals.
  • V i 114 the output of the analog multiplier 94 , represents V 1 116 , V 2 118 , V 3 120 and V 4 122 , which are generated by switching the inputs of the analog multiplier 94 circuit as shown in FIG. 6 .
  • the complex transducer 16 impedance Z can be calculated by dividing V by I , and the conductance G is the real portion of the inverse of Z , or the real portion of I over V .
  • the effective transmitted acoustic power P a can be calculated.
  • the voltage control signal V c 124 can then be adjusted and readjusted accordingly to maintain the delivery of acoustic power at a constant level.
  • the procedure used by the microprocessor 36 for determining the efficiency of the transducer is as follows: (1) determine vector voltage V i 114 , having components V 1 116 , V 2 118, V 3 120 and V 4 122 , by measurement; (2) calculate the coupling efficiency and the electric power from the vector voltage 114 ; (3) calculate the effective transmitted acoustic power; and (4) readjust the voltage control signal 124 accordingly.
  • the microprocessor 36 is thus able to maintain a constant level of effective acoustic power transmitted to the patient by adjusting the electric power approximately every 20 milliseconds in response to the coupling efficiency calculated in the feedback loop. Additionally, during emission, the microprocessor 36 regularly scans the G max 84 value in order to detect if f s 86 has shifted and readjusts accordingly.
  • the microprocessor 36 monitors the feedback loop, with notification provided if the feedback loop fails.
  • a failure of the feedback loop may occur, for example, when the user removes the treatment head 16 from the patient, which results in insufficient acoustic coupling. In the event of such a failure, transmission is stopped and the ultrasound therapeutic system 10 puts itself into resonance search and output calculation mode. Once the acoustic coupling returns to an acceptable level (by the user having placed the treatment head 16 back in contact with a patient's skin), the feedback loop is restarted and normal operation resumes.
  • the microprocessor 36 also monitors the resonant frequency 86 search and centering, and the presence of the treatment head 16 . Throughout, the system 10 continuously scans the frequency over a range around the nominal resonant frequency f s 86 to ensure that the frequency of the excitation signal remains centered on the maximum conductance G max 84 .
  • the ultrasound therapeutic system 10 in accordance with the present invention generally includes a calibration procedure that enables a user to calibrate the transducer treatment heads 16 whenever necessary without having to send the entire ultrasound therapeutic system 10 back to the factory.
  • the calibration procedure enables the user to calibrate an entirely new transducer treatment head 16 as soon as it is received, facilitating easy and efficient replacement of worn or dysfunctional parts.
  • the calibration procedure of the present invention automatically determines the impedance of the transducer treatment heads 16 .
  • the procedure is based upon the measurement of the series conductance G 0 of the transducer treatment head when it is unloaded.
  • the series conductance is the real portion of the admittance and the reciprocal of the impedance and represents the losses of the transducer treatment head 16 itself.
  • the microprocessor 36 calibration software scans the generator frequency to determine the maximum value of G 0 that also yields the resonant frequency f s 86 of the transducer treatment head 16 .
  • the measurement of G 0 is done by a demodulation method in which the current 98 and voltage signals 96 from the treatment head are multiplied by quadrature reference signals 106 and 108 .
  • This method considers the complex impedance and thus accounts for the corresponding phase shifts between current and voltage ( ⁇ ):
  • the complex admittance Y can then be determined, the real part of which is the series conductance G 0 :
  • the user initiates the calibration procedure. Ideally the procedure is run annually, but other periodic calibrations are envisioned as well.
  • the microprocessor 36 scans the excitation frequency in a predefined range around the resonant frequency 86 and looks for the maximum conductance G 0 .
  • G 0 is representative of the transducer 16 losses as it is the real portion of the impedance when no acoustic energy is produced by the piezo transducer 16 .
  • the microprocessor 36 records the value of G 0 and the resonant frequency 86 for later use.
  • this calibration procedure allows the system 10 to compensate for any changes in the electrical characteristics of the transducer 16 , including the acoustic load, changes in the capacitance C 0 due to aging, temperature driven changes, and like characteristics.
  • the system 10 considers both impedance amplitude and phase, allowing for consideration of complex changes.
  • the power transmitted to the tissue remains accurate despite shifts in the resonant frequency 86 due to slight imaginary components in the acoustic impedance of the target tissues being treated.

Abstract

The ultrasound therapeutic system of the present invention generally includes a generator unit, at least one transducer treatment head, and a programmable controller. The generator is in operable communication with the at least one transducer treatment head such that electric power outputted from the generator to the head is converted into acoustic power by the head. Re-programmable software at the controller generally controls all features and functions for the system. In particular, the controller calculates an initial optimal treatment dose, maintains effective acoustic power transmitted to the patient through the at least one treatment head, performs calibration procedures for the at least one treatment head, controls outputting for each supported treatment mode, and provides for various other features and functions.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • This application is a divisional application of co-pending U.S. application Ser. No. 10/281,090, entitled “Ultrasound Theropeutic Device,” filed on Oct. 25, 2002, which will issue as U.S. Pat. No. 6,860,852, Mar. 1, 2005.
  • FIELD OF THE INVENTION
  • The present invention generally relates to the field of ultrasound treatment. More specifically, the present invention relates to an ultrasound therapeutic device capable of automatically determining a considerate treatment dose, controlling acoustic power output efficiency, and performing adjustable calibration functions.
  • BACKGROUND OF THE INVENTION
  • Therapeutic ultrasound devices have long been utilized in the treatment of musculoskeletal and tissue injuries. Greater understanding of ultrasound, and the application of ultrasound to human skin and tissue, have expanded the scope of possible uses for these devices. For instance, in addition to the thermal or vibratory focus of more traditional devices, developments have been made in which ultrasound devices can be directed toward introducing various drugs into the human body through the skin. However, the increase in potential uses and advantages for these therapeutic ultrasound devices has come at a price. Namely, advancements in the technology and the understanding of the potential applications, has correspondingly led to the complication of setup procedures, inefficient power adjustments, and the need for more precise calibration procedures.
  • Initial Parameter Inputs
  • Ultrasonic therapy devices impose mechanical vibrations on tissue and skin to cause various thermal and non-thermal effects. An ultrasound generator outputs electric power to a treatment head. The treatment head includes a transducer which converts the power from the generator into ultrasonic energy or acoustic power. It is this acoustic power that is transmitted for therapeutic treatment through the patient's tissue. The requisite acoustic power can vary greatly depending on the treatment goals, the target tissue type, the target tissue depth, and other like factors. In addition, the duration of the ultrasonic treatment dosage to the patient is important. Treatment goals, the unique characteristics of the target tissue, and like considerations dictate the treatment duration.
  • Conventional ultrasound treatment devices generate a treatment dose based on manually inputted values or parameters. Parameters such as treatment time/duration, frequency, and treatment intensity are inputted by the end user. Generally, with such devices, calculations and determinations are made by the user. Consequently, it is up to the device user to come up with the ideal treatment parameters required for a specific patient, assuming specific treatment goals for that patient.
  • There are many drawbacks with manually operated devices. Specifically, it is problematic that these manual systems are reliant upon the skills and knowledge of the individual user. This problem manifests itself in at least two respects. First, there is no way to know or control exactly what factors are being considered by the user in calculating the proper treatment parameters. For example, there are no guarantees that the end user will properly consider the target tissue characteristics, the target tissue type, or the existence and depth of any intermediate tissue between the treatment head and the target tissue. These are all highly relevant factors that should play a primary role in determining the proper treatment outputs and durations for any effective ultrasound therapeutic treatment. In addition, accidental parameter entries, and the varying level of user training introduce still more uncertainty into the likelihood of providing optimized ultrasound treatment for the patient.
  • As indicated, the unique and specific characteristics of the target tissue, and the nature and thickness of intermediate tissue and/or the target tissue, are requisite factors to be considered in determining a proper ultrasound treatment dose. This is true since both the thermal and non-thermal effects of ultrasound are dependent upon these factors. Despite the fundamental importance of these considerations, conventional ultrasound therapeutic devices simply have not advanced methods and apparatus that properly consider and process known histological tissue characteristics in generating a treatment dose.
  • U.S. Pat. No. 5,413,550 (“the '550 Patent”) discloses an attempt to provide for considerate dose control. The '550 Patent is directed to an ultrasound device including a controller programmed to calculate a treatment dose. The treatment dose consists of treatment frequency, output intensity, and treatment time. The programmed controller determines and generates the dosage parameters based on the inputting of numerous treatment parameters by the end user. Specifically, the device requires values for the following primary treatment parameters in order to calculate a dosage: depth of tissue to be treated, the desired tissue temperature rise, the tissue area to be treated, and the selection of an ultrasound couplant. In addition the user may input the tissue type, and a duty factor value as secondary parameters. The device of the '550 patent performs routine checks to determine if treatment parameters have been entered. If the controller determines that specific primary treatment parameters have not been inputted, the controller circuitry inserts a default value in place of the missing parameter(s). As a result, it is possible to enter only one of the primary treatment parameters, with each of the remaining parameters being substituted for default values. Such a default-driven device and process is problematic and fails to properly focus the ultrasound treatment on ultrasound effects and histological tissue data.
  • The use of default parameters to calculate dosage, by definition, fails to take into account the unique circumstances and characteristics of the patient, the treatment goals for the specific target tissue of the patient, and like goals and considerations that are essential in providing highly efficient and effective ultrasound treatment. As indicated herein, knowledge and specific consideration of the unique target treatment tissue, and the depth of that tissue or the thickness of intermediate tissue, are essential in generating an optimal treatment dose. Generating a dose, regardless of the automated nature of the calculation, is deficient if it fails to account for the true tissue structure, such as the energy losses produced as a result of tissue heating, and the losses caused by adjacent tissue structure. Ignoring such essential characteristics of treatment on complex tissue structures dilutes the efficacy of the dosage calculation. Proper acoustic power outputs and treatment durations must be specified, monitored, and updated in a manner most beneficial for the treatment goals for the unique individual patient, after fully understanding and processing data pertaining to the target tissue, intermediate tissue, and tissue depths.
  • Treatment Dose Adjustments
  • Conventional ultrasonic therapeutic devices and systems are generally deficient when it comes to the continuous and efficient monitoring and controlling of the power being outputted from the generator to the transducer. The typical approach to controlling acoustic power from the transducer head is to merely provide alarm and display notices to the user. For example, U.S. Pat. No. 4,791,915 is directed to a device wherein the coupling efficiency between the transducer and the patient is displayed in the form of a readable bar graph for the user to observe and monitor. However, such systems and devices merely focus on preventing overheating and electrical shorting. Threshold comparisons are merely made in order to prevent catastrophic failures which could cause device malfunction and/or injury to the patient.
  • Other conventional ultrasound treatment systems implement adjustment techniques and controls directed to providing for a relatively constant electric power output level to the patient. For instance, U.S. Pat. No. 4,368,410 discloses an ultrasound therapy device wherein an optimal electric output power level is inputted into the device. Feedback signals from a driver circuit proportional to the transducer voltage and current are returned to an analog servo circuit and a voltage representing true electric power is calculated. If the output power represented by the voltage level increases then it is an indication that there is a reduction in the load on the transducer, and the drive signal is decreased. Similarly, if the instant voltage decreases, an increase in the signal is initiated to compensate for an increase in the load on the transducer. The innate problem with such a system is that while it does acknowledge the effects varying treatment techniques, treatment zones, and an individuals body can have on ultrasound treatment, it does not properly use this information in providing for a truly responsive individualized treatment dosage. Focus is on maintaining a constant electric power output and not on performing acoustic analysis. Events and circumstances effecting the ultrasound treatment are not properly considered—i.e, the introduction of intermediate tissue, the natural changes across a patient's body “zones”, and the like.
  • Treatment Head Calibration
  • Each treatment head of an ultrasound therapeutic device requires calibration. Primarily, this calibration is needed in order to accommodate and adjust for various innate properties and characteristics unique to particular heads. The head must be properly calibrated in order to correctly match the specific resonance frequencies of its constituent ceramic. For instance, each ceramic treatment head varies in its material properties. As a result, proper operation and acoustic output for each and every head mandates at least an initial head calibration. Typically, this calibration is done in the factory prior to receipt of the device by the end user. In many cases, this is the only calibration allowed for, and any later re-calibration must again occur at the factory. However, these factory calibrations are problematic since untimely degeneration can adversely affect treatment quality and effectiveness.
  • Even those conventional devices that permit for user-initiated calibration require the initiation of complicated or time-consuming procedures. Specifically, it is common to allow for user calibration by immersing the head in water and making a series of adjustments based on calibration readings displayed by the device. For obvious reasons, such techniques are undesirable and inconvenient. Additionally, conventional devices do not consider complex changes introduced by slight imaginary components in the acoustic impedance of the tissues being treated. Conventional devices are thus unable to transmit an accurate amount of power to the tissue or fully self-calibrate.
  • As a result, there is a need for an ultrasonic therapeutic device, and method for operating and controlling thereof, that substantially solves the problems and deficiencies described in the prior art.
  • SUMMARY OF THE INVENTION
  • The ultrasound therapeutic system and methods in accordance with the present invention substantially solve the problems and weaknesses present in the prior art devices and methods. The present invention is generally directed to an ultrasound treatment system wherein it is preferred that each of the described prior art deficiencies are addressed in one device. In general, the ultrasound device and methods of the present invention are directed to providing an optimal initial treatment dose based on complete processing of user-inputted histological tissue data, employing an automatic regulatory feedback loop to maintain optimal acoustic power output to the patient during operation, and providing a simple yet efficient user-initiated treatment head calibration technique. Further, the treatment system of the present invention includes multi-mode treatment techniques/effects, and user-specific memorization functions.
  • The ultrasound therapeutic system of the present invention generally includes a generator unit, at least one transducer treatment head, and a programmable controller. The generator is in operable communication with the at least one transducer treatment head such that electric power outputted from the generator to the head is converted into acoustic power by the head. Re-programmable software at the controller generally controls all features and functions for the system. In particular, the controller calculates an initial optimal treatment dose, maintains effective acoustic power transmitted to the patient through the at least one treatment head, performs calibration procedures for the at least one treatment head, controls outputting for each supported treatment mode, and provides for various other features and functions as will be discussed in further detail herein.
  • Unlike the prior art, the present invention is directed to intelligent and simplified automatic dosage determination. Specifically, the output dose is calculated by processing values inputted by the user for target tissue type, intermediate tissue type, and tissue depth/thickness. The present invention does not import or process arbitrary default values for treatment couplant, tissue configuration, and the like. Instead, dosage is based on the fundamental tissue data inputted, wherein the controller performs simulation comparisons to derive the smallest dosage needed to optimally achieve the therapeutic treatment effect. Further, the dosage determination of the present invention, through processing of the inputted histological tissue data, takes into account the relevant tissue layer structure to adjust for the effects caused by innate losses through tissue absorption and reflections caused by impedance discontinuities between different tissue layers. Wave reflection and absorption characteristics are dynamically considered in order to properly understand the resulting output that will be delivered to the target tissue of the patient in light of the relevant tissue structure.
  • The feedback loop of the present invention is also considerate in its function. Rather than seeking to maintain a constant electrical output, as is often practiced in conventional devices, the ultrasound device of the present invention controls and monitors the effects of the treatment on the transducer head to maintain a constant ideal acoustic power. As a result, changes that may occur naturally during treatment, such as changes caused by the innate acoustic properties of the tissues proximate the treatment head, are properly considered.
  • To ensure that the ultrasound device of the present invention is operating safely and effectively, the present invention includes an automatic calibration feature. This feature enables new and replacement treatment heads to be introduced without having to send the entire device away for calibration. The ultrasound device of the present invention automatically determines the complex impedance of the transducer head, after calibration, and maintains acoustic power even in the presence of changes in the real or imaginary portion of the acoustic impedance of the relevant tissue.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a front view of an embodiment of an ultrasound therapeutic device in accordance with the present invention.
  • FIG. 2 a is a diagram demonstrating ultrasonic beam absorption and reflection losses resulting from a specific human tissue structure.
  • FIG. 2 b is a block diagram of the operation of thermal dosage control in accordance with an embodiment of the present invention.
  • FIG. 3 is a diagram plotting the frequency versus conductance of a transducer in accordance with an embodiment of the present invention.
  • FIG. 4 a is a diagram of transducer circuitry in accordance with an embodiment of the present invention.
  • FIG. 4 b is a diagram of transducer circuitry in accordance with an embodiment of the present invention.
  • FIG. 5 is a block diagram of the ultrasound system in accordance with an embodiment of the present invention.
  • FIG. 6 is a diagram depicting the real and imaginary components of measured voltage and current in accordance with an embodiment of the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Referring primarily to FIGS. 1 and 5 , an ultrasound therapeutic system 10 in accordance with the present invention is shown. Specifically, the ultrasound system 10 generally includes a device housing 12 , a generator/output stage high frequency amplifier 14 , at least one transducer treatment head 16 , and a programmable controller 18 . The generator 14 and controller 18 are housed within the device housing 12 , and are both in operable communication with the transducer 6 via a frequency cable 20 .
  • The generator 14 , as shown in FIG. 5, is an electric power source commonly understood by one skilled in the art. For instance, a 48 Volt dc, 0.85 Amp main power source can be utilized in one embodiment, while others could implement similar compatible units. First and second working frequencies of the generator 14 are preferably approximately 1.017 MHz and 3.2 MHz, respectively. It is possible to have a measurable tolerance/deviation of +/−30 KHz on the first frequency and +/−50 KHz on the second frequency. Other output frequencies and permissible frequency tolerances understood to one skilled in the art are also envisioned. The electric power frequency outputs are outputted from the generator 14 to the transducer head 16 through the frequency cable 20.
  • The at least one transducer treatment head 16 is a transducer head of a predetermined size, with the head 16 generally including a handling portion 26, a transducer element 28, and a treatment surface 30 . Each treatment head 16 utilized for the present invention is preferably watertight for optimal use even if completely submerged. Various embodiments can employ different sized treatment heads 16. For instance, ultrasound treatment needs and human body structure and size for a specific focus treatment region on an individual can influence the size of the treatment head. Generally, a large and small head will be interchangeable using the same frequency cable 20. The ultrasonic transducer element 28 of the treatment head 16 is typically constructed of a ceramic (piezo) material. As such, the element 28 will have a maximum output of acoustic power substantially at its resonance frequency. As will be further discussed herein, the treatment head 16 will require initial and, perhaps, periodic self-calibration to guarantee that this optimal resonance frequency for the respective transmission element 28 is obtained and maintained. While various treatment heads 16 can be exchanged to meet specific ultrasonic treatment requirements, there is no need to switch out the cable 20. Conventional devices utilize a unique cable for each treatment head, a practice that can be quite costly, and that can make transportation and storage cumbersome and inconvenient. As discussed herein in describing the cable 20, the present invention eliminates this innate drawback found in conventional devices.
  • In one embodiment of the present invention, the treatment head 16 further includes a configuration monitoring chip to measure, observe and store data. For instance, operation temperature at the head 16, head 16 serial numbers, head size, calibration data, and a myriad of other information can be stored such that the controller 18 in operable communication with the head 16 can store data to, and retrieve data from, the head 16. This storage and reprogramming can be accomplished with the use of EEPROM, or other non-volatile memory and storage technologies. For instance, a Dallas DS-1820 chip (manufactured and sold by Dallas Semiconductor of Dallas Texas), or other chips capable of performing these storage and monitoring functions can be utilized without deviating from the spirit and scope of the present invention.
  • The frequency cable 20 shown in FIG. 1 generally includes at least one set of end connectors 34 and 35 sized and shaped for connecting to respective system 10 components. In particular, at least one end connector 35 can be removably connected to the generator 14 at the housing 12 and the distal end connector 34 of the same cable 20 can be removably connected to the transducer treatment head 16. As such, various treatment heads 16 can be exchanged for operable use with the one common cable 20. This unique swap/exchange feature is possible due to the selectively engageable distal end connector 34. Unlike conventional practice, a fixed and head-specific cable is avoided such that the present invention promotes interchangeability and treatment flexibility, while at the same time promoting storage and transportation. Each of the end connectors 34 and 35 is generally combined or connected to a system component via a socket or plug connection to facilitate maintenance, selective replacement, and adjustable configuration, with each connection preferably being watertight.
  • Referring primarily to FIG. 5, the controller 18 includes a microprocessor 36 and control circuitry for providing re-programmable software and hardware control of the present invention. The microprocessor 36 is programmed to receive input and execute control software/algorithms in accordance with predetermined and inputted data. The microprocessor 36 is housed within the housing 12 and is in operable communication with the generator/output stage high frequency amplifier 14, treatment head 16, and each of the other components directly and/or through the controller 18. In various embodiments, flash ROM, EEPROM, non-voltaile memory, and RAM can be employed in conjunction with the microprocessor 36 at the controller 18 for data storage and retrieval.
  • Referring again to FIG. 1, the housing 12 generally includes a data input portion 38 and a display portion 40. The input portion 38 can comprise input keys or other known input devices for receiving data inputted by an end user in response to prompting from the display portion 40 or from volitional decisions to pursue known treatment goals and program routines. The data input portion 38 and display portion 40 are in operable communication with the controller 18.
  • In operation, the system 10 of the present invention can prompt the end user to input specific individualized treatment data, wherein the controller 18 can utilize the data to calculate and initiate ultrasound treatment, and provide responsive output and interface adjustments during treatment. In one embodiment, a treatment session or use of the system 10 will involve the following series of inputs, outputs, and automatic adjustments.
  • First, a treatment “type” must be inputted into the system 10 via prompting on the display portion 40 . Generally, there are at least three treatment types: thermal, biological, and phonophoresis. Thermal allows the end user or patient to receive a thermal energy effect from the treatment head 16 at the treatment surface 30. Specifically, such a treatment selection initiates a specific device configuration at the controller 18 wherein the ultrasound energy transmission is converted into thermal energy. Such a conversion leads to a local temperature elevation which particularly effects deeper dense tissue of the patient. As further discussed herein, the proper ultrasound transmission is highly dependent upon inputted histological data from the patient/end user.
  • The selection of a biological treatment type is directed to a pulsed ultrasound output mode wherein the pulse causes the oscillation of molecules accompanied by marked pressure variations. In turn, this oscillation can lead to the formation of micro-bubbles by cavitation, which in turn can produce a beneficial micro-traumatic stress in indurated tissues, inflammatory foci, local calcified accumulations, and the like.
  • The selection of a phonophoresis treatment type permits the patient to take advantage of the increased skin permeability that accompanies ultrasound waves. Radiation pressure at the skin due to the inherent permeability increase promotes penetration of medicines through the epidermis layer of the patient. With this treatment selection, there is generally no need for the patient to input histological data or treatment parameters since ideal penetration of the substance is predetermined to facilitate performance and efficiency. In one embodiment, the selection of the phonophoresis treatment mode will cause the microprocessor 36 to set the treatment parameters to the following values: intensity=1.5 W/cm2; duration=8 minutes; frequency=3.2 MHz; emission mode=pulsed; duty cycle=½. Other variations on these values are envisioned and can be employed and pre-programmed into the microprocessor 36 software without deviating from the spirit and scope of the present invention.
  • In addition, a manual setting is selectable so that the patient can control each of the relevant microprocessor-controlled treatment parameters—intensity, duration, frequency, and emission mode. However, in preferred embodiments, these treatment parameters are calculated and adjusted automatically by the controller 18 implementing software algorithms running on the microprocessor 36.
  • Specifically, in thermal and biological treatment modes, histological structure data for the individual patient is needed. This histological data generally comprises the target tissue type (tissue to be treated), and the intermediate tissue type and depth (subcutaneous tissue, if any, between the device and the target tissue). Accurate calculation and inputting of this limited histological data will provide the microprocessor 36 with enough information to provide for a highly controlled and efficient treatment of the patient. The necessary treatment parameters and treatment dosage can be selectively and effectively controlled having only this histological data from the patient/user.
  • The target tissue is generally selected at the input 38 panel of the system 10 from a programmable list. This list can comprise bone, muscle, fat, aponeurosis, tendon, or other targets known to one skilled in the art. In some circumstances, the target tissue will be the only inputted/selected histological data. For instance, if the target tissue is fat, there may not be an intermediate tissue to take into account in controlling the ultrasound treatment to the patient. As such, only the depth of the fat target tissue will need to be inputted.
  • In other circumstances, the effect of relevant intermediate tissue must be accounted for in determining a treatment dosage. For example, in one operating scenario the target tissue selection may be muscle. As such, it may be necessary to input the thickness or depth of the intermediate tissue between the treatment head 16 and the target muscle tissue. The intermediate tissue depth can be measured with the use of skinfold pinch calipers, estimated on the basis of the physician's or therapist's knowledge of human anatomy (i.e., palpatory anatomy), and the like. The microprocessor 36 can take the inputted histological data alone and determine the proper intensity, duration, frequency, and emission mode. The software will generally select the individual treatment parameters from the following range list: intensity=0 to 2.3 W/cm2; duration 0 to 30 minutes (1800 seconds); frequency=approximately 1 or 3 MHz; emission mode=continuous (1/1) or pulse (1/2, 1/4, or 1/8).
  • Upon the inputting of user selections and the computed parameter settings and feedback controls, the treatment session will begin by applying the treatment head to the target location on the patient. The treatment head 16 output dosage is controlled by the controller 18. If at any time the head 16 is removed from the patient during the designated treatment period, for a predefined period of time, the controller 18 will initiate a shut down procedure to stop output from the generator 14 to the treatment head 16.
  • Thermal Treatment Mode
  • In thermal mode, the algorithmic simulation functions of the microprocessor 36 automatically calculate and control the treatment dosage to create a tissue temperature elevation based on the relevant histological data. Preferably, the intensity and duration parameters are fully correlated. A change, either manually or automatically, will cause the microprocessor 36 software to automatically change the remaining value correspondingly such that the product of the at least two values remains substantially unchanged. The product of intensity and duration is generally used to produce a target tissue temperature elevation of 7 degrees Celsius. A continuous transmission (1/1), rather than pulsed, is typically initiated by the software in thermal mode since such a transmission promotes the desired tissue temperature elevation.
  • This product of acoustic intensity and treatment duration is the treatment dosage. As shown in FIG. 2 a, the dosage is a function of the losses from absorption of the ultrasound beam as it travels through relevant tissues and the losses from reflections at the interfaces between adjacent tissues having different acoustic impedances. The quantity of ultrasound which ultimately reaches the target tissue is the therapeutically effective energy which participates in the local elevation of tissue temperature. Since the temperature elevation depends on dosage, the user can change the remaining treatment duration or the intensity at anytime.
  • The software selects the frequency of the output signal based on the histological data inputted. Specifically, the target depth and intermediate tissue dictate the level of penetration required to provide an effective therapeutic dose. In one embodiment, a frequency of approximately 1 MHz is utilized to penetrate relatively deep tissue since such a signal will be less absorbed by the tissue. Conversely, a frequency of approximately 3 MHz is utilized to penetrate relatively shallow tissue. Preferably, the microprocessor 36 software performs simulations at both the 1 MHz and 3 MHz levels to determine which signal will require the smallest dosage while still obtaining the requisite therapeutic effect. Other predetermined or variable frequency determinations can be made as well without deviating from the spirit and scope of the present invention.
  • Referring to FIG. 2 b, one embodiment of the automatic mode dosage determination software is shown. First, the user is required to enter specific data at an initial input stage 50. At this data input stage 50, the user is first prompted to enter a target tissue type. Generally, fat, muscle, tendon, and bone are the tissue types available for selection or input. Once the tissue selection has been made, the user is prompted to input the depth of the tissue between the target and the treatment head 16. It is preferred that this depth be entered in centimeters, but other measurements are also envisioned. For instance, if the target tissue inputted is tendon, it is possible that there is muscle and/or fat intermediate the tendon. As discussed, this tissue intermediate the target tissue must be considered before calculating a truly effective treatment dosage. Tissue depth and thickness calculations can be performed using techniques known to one skilled in the art. For instance, pinch calipers and the physician's or therapist's knowledge of the human anatomy can be employed. Depending on the presence of intermediate fat or muscle, and the corresponding depth for the intermediate tissue, the microprocessor 36 software will process the data at an intensity transmission stage 52.
  • At the intensity transmission stage 52, the actual transmission effects of the tissue layer structure are considered in calculating a transmission coefficient τ. Variable τ represents reflection losses caused as a result of the layers and tissue interfaces to assist in providing for needed adjustment in the dosage, wherein τ is represented in equation form as:
    τ=1−R ij
    where Rij is the tissue intensity reflection coefficient between layer i and j. This reflection coefficient depends on the acoustic impedance of layer i (Zi) and layer j (Zj): R i j = ( z i - z j ) 2 ( z i + z j ) 2
    Defined tissue impedance levels for bone, skin, tendon, muscle, and fat are known and processed depending on the referenced tissue inputs such that each impedance value corresponds to a wave reflection at the interface of adjacent tissues. For instance, a τ value representing the influence of the reflection characteristics of interfacing fat and tendon tissue (τft ) will equate to a coefficient of 0.934, which represents a 93.4% transmission intensity and a 6.6% loss due to reflections at the interface. Assuming m=muscle, t=tendon, f=fat, and b=bone, other possible transmission loss characteristics can be accounted for as τmt=0.974, τst=0.968, τsb=0.748, τfb=0.685, τmb=0.761, τfm=0.990, τfs=0.990, τsm=0. 890, τtb =0. 870, and other transmission coefficients known to one skilled in the art.
  • Additionally, reduction of the available energy at the target tissue is caused by a beam attenuation (a) phenomenon. First, this attenuation is due to absorption (α), which is a transformation of a fraction of the acoustic beam into heat. Second, beam diffusion or scattering (d) also contributes to the beam attenuation. As such, a=α+d. For scenarios involving soft tissues and at frequencies in the MHz range, scattering may be neglected so that a=α, for a unit measurement of Np/cm2 (Nepers per square centimeters).
  • At the thermal simulation stage 54, the appropriate ultrasound frequency intensity (I0) and treatment duration (T) are calculated such that the product of the intensity and the treatment duration equals the treatment radiation dosage D. In obtaining the correct variables for this dosage formula, an ideal frequency must be calculated. This ideal frequency for the ultrasound intensity I0 is based on a simulation run for at least two frequencies—1 MHz and 3 MHz. It should be noted that these frequencies, while preferred, are not in any way exhaustive in nature. For instance, other frequency ranges and values can be utilized depending on the particular desired therapeutic effect. In addition, values such as 1 MHz and 3 MHz are obviously rounded for ease of explanation an9d calculation. In one embodiment, the frequency intensities can be assigned as 1.017 MHz±30 KHz, and 3.2 MHz±50 KHz. Other values and corresponding ranges are also envisioned.
  • In an embodiment performing an individual simulation run for both 1 MHz and 3 MHz levels, the following equation is implemented: D = ( I 0 · t ) = T C v 2 α · f · τ 2 f ( a1e1 + a2e2 + a3e3 )
    wherein the frequency value ƒis inserted by the microprocessor 36 program as either 1 or 3 depending on the particular simulation run, T is the treatment duration (i.e., seconds), Cv is a thermal coefficient (heat capacity per unit volume), a is the attenuation coefficient, and τ again represents consideration of the effects of the actual tissue layer structure in an intensity transmission coefficient. As the appropriate τ value has already been processed in the intensity transmission stage 52, that value is automatically inserted to promote evaluation of true tissue effects during the treatment simulation. The attenuation coefficient a represents absorption within the tissue layer of a level of energy lost in the form of heat. Variable attenuation coefficient values known to one skilled in the art as being representative of these tissue-specific heat absorption effects can be employed without deviating from the spirit and scope of the present invention.
  • With calculation and insertion of the appropriate values into the simulation equation, a product A is assigned the resulting dosage product for 1 MHz, and B is assigned the dosage product for 3 MHz. The products A and B are compared and analyzed to determine the smallest dose D that can be employed while still reaching the desired therapeutic effect based on known histological data from the user. Preferably, if A≧B then a value of 3 MHz is assigned as the output frequency, else a value of 1 MHz is assigned. Next, intensity and treatment duration end points are examined based on the simulation results to determine optimum values for generating the product dosage, wherein the resulting product dosage is processed to determine whether it falls within an acceptable range defined by predetermined minimum and maximum product dosage values. These values, in one embodiment, can be a minimum dosage value of 6 Ws/cm 2 (Watt seconds per square centimeter) and a maximum value of 5400 Ws/cm2. For instance, if a maximum product dosage of 5400 is calculated based on the above simulation equations, then a set intensity I0, is assigned to approximately 3 W/cm2, with a corresponding treatment duration of approximately 1800 seconds. Further, the microprocessor 36 can downsize the dosage if it exceeds the maximum, up the dosage if it equates to a value below the acceptable minimum level, and can process variable levels between these end point values. At the completion of the comparison and simulation, the duration T, and intensity I0 are known values that can be linked at a product dosage stage 56, wherein the product dosage P=I0·T. This equation links the variables such that a change in one variable can cause the microprocessor 36 program to correspondingly change the other variables to produce a constant dosage.
  • Biological Treatment Mode
  • In biological mode, the algorithmic simulation functions of the microprocessor 36 take tissue configuration into account and automatically select the treatment parameters that will produce the required mechanical effect and minimize tissue temperature elevation. Whereas a tissue temperature elevation is the desired effect in the thermal treatment mode, a thermal effect is not beneficial and must be minimized in biological mode in favor of a mechanical effect.
  • The software automatically determines the intensity, frequency, emission mode and duration of treatment needed in biological mode. In one embodiment, these values are obtained from a look-up table. The desired mechanical effects of biological mode are typically induced using a pulsed emission mode with different duty cycles. The ultrasonic pressure waves produce an oscillation of molecules in the target tissue. This oscillation creates microscopic bubbles called cavitation bubbles that generate small shockwaves in the tissue when they collapse. These small shockwaves induce microscopic mechanical effects in the tissues that enhance the healing process by causing the tissues to grow stronger in reaction to the micro-traumatic stress effect. Biological mode is typically beneficial to indurated tissues, inflamed areas, local calcifications, accumulations of blood such as hematomas, bruises and blood clots, and areas of fibrosis.
  • Phonophoresis Treatment Mode
  • In phonophoresis mode, ultrasound is employed to aid in the penetration of drugs through the skin and into target tissue. Phonophroesis mode enhances local application of a drug by increasing the permeability of the skin and exerting a radiation pressure that promotes the penetration of drugs deep into tissues.
  • In one embodiment, all software parameters in phonophoresis mode are fixed and the dose is held constant. While the intensity and treatment duration may be adjusted, the microprocessor 36 software links the two conditions inversely such that an increase inputted in either will cause the software to decrease the other. Again, phonophoresis treatment mode will generally cause the microprocessor 36 to set the treatment parameters to the following values: intensity=1.5 W/cm2; duration=8 minutes (480 seconds); frequency=3.2 MHz; emission mode=pulsed; duty cycle=½.
  • Automatic Feedback Loop
  • Ultrasound treatment is more effective when constant acoustic power is delivered to the tissue. The ultrasound generator 14 includes a novel feedback loop feature that operates to maintain the delivery of acoustic power at a constant level. A simplified block diagram 100 of the feedback loop in accordance with the present invention is shown in FIG. 5.
  • The feedback loop operates to measure a coupling efficiency between the transducer treatment head 16 and the biological tissue of the patient. The coupling efficiency is a ratio of the acoustic power effectively transmitted into the patient to the electric power delivered to the transducer treatment head 16 from the generator 14 . Thus, the coupling efficiency can be expressed as: η = P a P e
    where η is the coupling efficiency, Pa is the effective transmitted acoustic power and Pe is the delivered electric power. The coupling efficiency is dependent on patient tissue configuration as tissue impedance varies with tissue type. For example, if the tissue in contact with the transducer treatment head 16 is soft, i.e., skin with a thick layer of fat, the acoustic impedance will be low and the coupling efficiency will be low. If the tissue is instead skin with a thin layer of fat and a large bone near the skin surface, the coupling efficiency will be higher.
  • The microprocessor 36 adjusts the electric power, Pe , such that the effective acoustic power transmitted to the patient is maintained constant regardless of the tissue type encountered. While the coupling efficiency, η, can be expressed by the above equation, the microprocessor 36 uses a modified equation to calculate η and determine the transducer efficiency for the purpose of adjusting the electric power to maintain the acoustic power.
  • FIG. 4 a depicts an equivalent circuit 88 of the piezo transducer close to its resonant frequency in accordance with the present invention. In the equivalent circuit 88, internal mechanical losses are represented by R i 92, and R r 90 represents the radiation resistance. The acoustic power emitted can be viewed as the power dissipated across the radiation resistance, R r 90. Where Rs represents the sum of R i 92 and R r 90, the value of Rs can be obtained by measuring the overall admittance (the reciprocal of the overall impedance) of the equivalent circuit at resonant frequency. At resonant frequency, C s 74 and L s 76 resonate together and further reduce the equivalent circuit 88 to the circuit 78 depicted in FIG. 4 b. The overall (complex) admittance, Y 80, of the circuit 78 (and the equivalent circuit 88 of FIG. 4 a) is the sum of the admittance of the resistance Rs (where Rs=Rr+Ri) and the admittance of the capacitor C 0 82, such that: Y _ = Y R + Y C = G + j B = 1 R s + 1 j ω C 0
    where G, the conductance, is the real portion of the admittance and B, the susceptance, is the imaginary portion. Thus, the conductance, G, of the equivalent circuit 88 of the transducer at resonant frequency is 1/Rs, which results in the value of Rs itself.
  • FIG. 3 is a diagram plotting the frequency 72 versus conductance 70 of a transducer 16 in accordance with the present invention. To measure the value of Rs, it is necessary to find the maximum value of the real portion of the admittance, G max 84, where G max = 1 R s
    This will also provide the series resonant frequency, f s 86. The equation for Y 80, above holds true only at the resonant frequency f s 86, of the piezo transducer 16, defined by the maximum of the real portion of Y 80, G max 84. FIG. 4 depicts the shape of a curve of the conductance, G 70, plotted against frequency, f 72, and demonstrates the relationship between G max 84 and f s 86. Note that the series resonant frequency f s 86 will vary for each transducer treatment head 16 used. Calibration of a particular transducer treatment head 16 consists of the microprocessor scanning the frequency of the signal and simultaneously monitoring the conductance, G 70, in order to detect a maximum (see FIG. 3). The locus of the maximum, G max 84, defines the resonant frequency, f s 86. This calibration procedure is initiated by a user while the transducer 16 is unloaded (e.g., not in contact with any tissue) and is discussed in greater detail in the following section.
  • Referring again to FIGS. 4 a and 4 b, the effective radiation resistance R r 90 actually represents the transmission of ultrasonic energy out of the transducer. When measuring the transducer radiating into a tissue load, the maximum conductance, G max 84 of FIG. 3 as discussed above, actually provides: G max = G tissue = 1 R tissue + R i
    When the maximum admittance is measured without any load, the maximum conductance, Gmax 84 (the real portion of the admittance), is almost exclusively the internal losses: G max = G 0 = 1 R i
    where G0 is the series conductance of the unloaded transducer treatment head 16. Thus, if the dielectric losses are neglected, the transducer 16 efficiency can be approximated by: η ea = G 0 - G tissue G 0
  • FIG. 5 represents a block diagram of the ultrasound system in accordance with an embodiment of the present invention. In operation, the analog multiplier 94 receives a measured voltage signal 96 and a measured current signal 98 from the generator/output stage high frequency amplifier 14. The analog multiplier 94 is also connected to a 90-degree quadrature signal generator 104. The 90-degree quadrature signal generator 104 receives a reference sine wave 110 from the digital sine wave generator 112 and in turn provides the analog multiplier 94 with sine 106 and cosine 108 reference signals. Vector voltage Vi 114, the output of the analog multiplier 94 , represents V 1 116, V 2 118, V 3 120 and V 4 122, which are generated by switching the inputs of the analog multiplier 94 circuit as shown in FIG. 6.
  • The electrical power Pe, can then be calculated from Vi 114, where:
    P e =|{right arrow over (V)}|·|{right arrow over (I)}|cos φ
    The complex transducer 16 impedance Z can be calculated by dividing V by I, and the conductance G is the real portion of the inverse of Z, or the real portion of I over V. After the efficiency η and the electric power Pe are calculated from the input voltage, the effective transmitted acoustic power Pa can be calculated. The voltage control signal V c 124 can then be adjusted and readjusted accordingly to maintain the delivery of acoustic power at a constant level.
  • In sum, the procedure used by the microprocessor 36 for determining the efficiency of the transducer is as follows: (1) determine vector voltage Vi 114 , having components V 1 116 , V 2 118, V 3 120 and V 4 122, by measurement; (2) calculate the coupling efficiency and the electric power from the vector voltage 114; (3) calculate the effective transmitted acoustic power; and (4) readjust the voltage control signal 124 accordingly. In operation, the microprocessor 36 is thus able to maintain a constant level of effective acoustic power transmitted to the patient by adjusting the electric power approximately every 20 milliseconds in response to the coupling efficiency calculated in the feedback loop. Additionally, during emission, the microprocessor 36 regularly scans the G max 84 value in order to detect if f s 86 has shifted and readjusts accordingly.
  • Further, during transmission the microprocessor 36 monitors the feedback loop, with notification provided if the feedback loop fails. A failure of the feedback loop may occur, for example, when the user removes the treatment head 16 from the patient, which results in insufficient acoustic coupling. In the event of such a failure, transmission is stopped and the ultrasound therapeutic system 10 puts itself into resonance search and output calculation mode. Once the acoustic coupling returns to an acceptable level (by the user having placed the treatment head 16 back in contact with a patient's skin), the feedback loop is restarted and normal operation resumes. The microprocessor 36 also monitors the resonant frequency 86 search and centering, and the presence of the treatment head 16 . Throughout, the system 10 continuously scans the frequency over a range around the nominal resonant frequency f s 86 to ensure that the frequency of the excitation signal remains centered on the maximum conductance G max 84 .
  • Automatic Calibration
  • For safe and effective ultrasound treatment, properly calibrated equipment is required. The ultrasound therapeutic system 10 in accordance with the present invention generally includes a calibration procedure that enables a user to calibrate the transducer treatment heads 16 whenever necessary without having to send the entire ultrasound therapeutic system 10 back to the factory. In addition, the calibration procedure enables the user to calibrate an entirely new transducer treatment head 16 as soon as it is received, facilitating easy and efficient replacement of worn or dysfunctional parts.
  • The calibration procedure of the present invention automatically determines the impedance of the transducer treatment heads 16. The procedure is based upon the measurement of the series conductance G0 of the transducer treatment head when it is unloaded. The series conductance is the real portion of the admittance and the reciprocal of the impedance and represents the losses of the transducer treatment head 16 itself. Referring primarily to FIG. 5, the microprocessor 36 calibration software scans the generator frequency to determine the maximum value of G0 that also yields the resonant frequency f s 86 of the transducer treatment head 16. The measurement of G0 is done by a demodulation method in which the current 98 and voltage signals 96 from the treatment head are multiplied by quadrature reference signals 106 and 108. This method considers the complex impedance and thus accounts for the corresponding phase shifts between current and voltage (θ): Z _ = V _ I _ = Z - j θ
    where θ is the phase of the complex impedance. The complex admittance Y can then be determined, the real part of which is the series conductance G0 :
    G 0 =Re{Y}=(R −1)
    where R=Rs=Ri as Rr=0 with no acoustic loading (see FIGS. 4 a and 4 b ). During the emission of ultrasound energy into a patient's tissue, the ultrasound therapeutic system 10 constantly measures the maximum series conductance under load, Gtissue , using the same method: G tissue = 1 R s = 1 R r + R i
    The system 10 then determines the real-time electro-acoustic coupling efficiency η: η = G 0 - G tissue G 0
  • In operation, the user initiates the calibration procedure. Ideally the procedure is run annually, but other periodic calibrations are envisioned as well. With the transducer 16 unloaded, the microprocessor 36 scans the excitation frequency in a predefined range around the resonant frequency 86 and looks for the maximum conductance G0. G0 is representative of the transducer 16 losses as it is the real portion of the impedance when no acoustic energy is produced by the piezo transducer 16. The microprocessor 36 records the value of G0 and the resonant frequency 86 for later use.
  • During normal use, the electro-acoustic coupling efficiency η is calculated from the actual loaded conductance Gtissue, where Gmax=Gtissue, and from the recorded value of G0 adjusted according to the equation above. In one embodiment, this calibration procedure allows the system 10 to compensate for any changes in the electrical characteristics of the transducer 16, including the acoustic load, changes in the capacitance C0 due to aging, temperature driven changes, and like characteristics.
  • In this automatic calibration procedure, the system 10 considers both impedance amplitude and phase, allowing for consideration of complex changes. Thus, the power transmitted to the tissue remains accurate despite shifts in the resonant frequency 86 due to slight imaginary components in the acoustic impedance of the target tissues being treated.
  • Those skilled in the art will appreciate that other embodiments in addition to the ones described herein are indicated to be within the scope and breadth of the present application. Accordingly, the applicant intends to be limited only by the claims appended hereto.

Claims (43)

1. A method of calibration for an ultrasound therapeutic treatment head, comprising the steps of:
determining the presence of a treatment head in an ultrasound system;
obtaining identification information for the treatment head;
performing a frequency scan around a theoretical resonant frequency using stepped intervals to determine a maximum unloaded conductance value of the treatment head and a corresponding resonant frequency;
storing the maximum unloaded conductance value and the resonant frequency value;
calculating a maximum series conductance under load of the treatment head;
calculating a real-time acoustic coupling efficiency of the treatment head from the maximum unloaded conductance value and the maximum series conductance under load; and
compensating for real and complex changes in the electrical characteristics of the treatment head according to the calculated real-time acoustic coupling efficiency.
2. The method of claim 1, wherein the step of obtaining identification information for a treatment head further comprises retrieving stored identification information from the controller.
3. The method of claim 1, wherein the step of determining the presence of a treatment head further comprises introducing a new treatment head to the ultrasound system.
4. The method of claim 1, wherein the step of determining the presence of a treatment head further comprises reintroducing a previously calibrated treatment head to the ultrasound system.
5. The method of claim 1, wherein the step of obtaining identification information further comprises reading data stored electronically for the treatment head by a controller in operable communication with the treatment head.
6. An automatic calibration system for use in an ultrasound system for physical therapy comprising:
a generator for generating an ultrasound output signal;
at least one ultrasonic transducer capable of receiving the ultrasound output signal to generate an acoustic output;
an input device for receiving histological tissue data from a user including target treatment tissue type; and
a controller running treatment software and calibration software, wherein the inputted histological tissue data is processed to generate an acoustic intensity value and a treatment duration value.
7. The system of claim 6, wherein the calibration software operably calculates an acoustic coupling efficiency from an actual loaded conductance and an unloaded series conductance to compensate for changes in the electrical characteristics of the ultrasonic transducer.
8. The system of claim 6, wherein the calibration software operably considers both impedance amplitude and phase to account for complex changes in the ultrasonic transducer and the ultrasound system.
9. The system of claim 6, wherein the at least one ultrasonic transducer is new to the ultrasound system.
10. The system of claim 6, wherein the at least one ultrasonic transducer is an ultrasonic transducer that has been previously calibrated by the ultrasound system.
11. An automatic calibration system for use in an ultrasound system for physical therapy comprising:
means for generating an ultrasound output signal;
at least one ultrasonic transducer capable of receiving the ultrasound output signal to generate an acoustic treatment output;
an input device for receiving histological tissue data from a user including target treatment tissue type, and intermediate tissue structure;
means for running treatment software, wherein the inputted histological tissue data is processed to calculate an ultrasound dosage including an acoustic intensity value and a treatment duration value; and
means for making a calibration adjustment to the ultrasound system that considers impedance amplitude and phase and accounts for complex changes in the electrical characteristics of the ultrasonic transducer.
12. A method of monitoring and controlling the acoustic power delivered to a treatment head of a therapeutic treatment system using a feedback loop, comprising the steps of:
applying electric power from a generator to a treatment head to generate an acoustic power output;
measuring, at a controller in operable communication with the generator, treatment head voltage values at stepped intervals;
calculating at the controller a coupling efficiency of the treatment head and an applied electric power from the measured treatment head voltage values at stepped intervals;
calculating at the controller an effective transmitted acoustic power; and
adjusting the electric power from the generator in response to the calculated coupling efficiency in order to maintain a constant level of effective acoustic power transmitted.
13. The method of claim 12, wherein the step of calculating at the controller a coupling efficiency of the treatment head further comprises:
measuring a vector voltage output of a multiplier in the feedback loop; and
calculating the coupling efficiency of the treatment head and the applied electric power using the vector voltage output.
14. The method of claim 12, wherein the step of adjusting the electric power includes performing the adjustment every 20 milliseconds.
15. The method of claim 12, further comprising the step of notifying a user of the therapeutic treatment system if a feedback loop failure occurs.
16. The method of claim 15, further comprising:
suspending the transmission of electric power from the generator;
commencing a resonance search and output calculation mode;
monitoring the output for a minimum tolerance; and
restarting the feedback loop and resuming normal operation when the output surpasses the minimum tolerance.
17. A feedback loop for monitoring and controlling the acoustic power delivered to a treatment head of a therapeutic treatment system comprising:
at least one ultrasonic transducer capable of receiving an ultrasound output signal to generate an acoustic treatment output;
a generator unit in operable communication with the ultrasonic transducer for generating the ultrasound output signal;
a voltage converter in operable communication with the generator unit to supply a voltage control signal;
a controller running treatment software, wherein inputted histological tissue data is processed to calculate an ultrasound dosage including an acoustic intensity value and a treatment duration value, and wherein the controller is in operable communication with the voltage converter;
an analog multiplier in operable communication with the generator to receive measured voltage and current signals and the controller adapted to supply a vector output signal;
a quadrature signal generator in operable communication with the analog multiplier to provide reference signals; and
a digital sine-wave generator in operable communication with the controller, the generator unit to provide a reference wave, and the quadrature signal generator to provide a reference wave.
18. The feedback loop of claim 17, wherein a coupling efficiency is calculated in the controller and the voltage control signal supplied to the generator unit is adjusted to operably maintain a constant level of effective acoustic power transmitted from the ultrasonic transducer to a user.
19. The feedback loop of claim 18, wherein the constant level of acoustic power transmitted to the user is maintained by adjusting an electric power in response to the coupling efficiency calculated by the controller.
20. The feedback loop of claim 19, wherein the electric power is adjusted every 20 milliseconds.
21. The feedback loop of claim 18, wherein the controller scans a maximum conductance value of the ultrasonic transducer to detect a shift in a resonant frequency and readjust the electric power in response.
22. A method of ultrasound therapy with a system having a generator, a treatment head, and a programmable controller in operable communication with the generator and the treatment head, comprising the steps of:
inputting histological tissue data by a user, the histological tissue data representing at least tissue type and tissue depth data;
inputting a treatment mode from a selection of thermal, biological, and phonophoresis;
automatically configuring treatment dosage parameters at the controller based on the inputted histological tissue data and treatment mode;
monitoring the operation of the system during treatment of a user; and
maintaining a constant acoustic power transmitted to the user during online use according to values received at the controller from the treatment head.
23. The method of claim 22, wherein the step of monitoring the operation of the system during treatment of a user further comprises:
monitoring a feedback loop within the system for failure;
monitoring a resonant frequency search and centering;
monitoring a presence of the treatment head; and
monitoring a temperature of the treatment head.
24. The method of claim 22, wherein the step of maintaining a constant acoustic power further comprises the steps of:
applying electric power from a generator to the treatment head to generate an acoustic power output;
measuring, at a controller in operable communication with the generator, treatment head voltage values at stepped intervals;
calculating at the controller a coupling efficiency of the treatment head; and
adjusting the electric power from the generator in response to the calculated coupling efficiency in order to maintain a constant level of effective acoustic power transmitted.
25. The method of claim 24, wherein the step of calculating at the controller a coupling efficiency of the treatment head further comprises:
measuring a maximum conductance of the treatment head in an unloaded state;
measuring a maximum conductance of the treatment head in a loaded state; and
calculating the coupling efficiency of the treatment head using the measured maximum conductance of the treatment head in an unloaded state and the measured maximum conductance of the treatment head in a loaded state.
26. The method of claim 24, wherein the step of adjusting the electric power is performed every 20 milliseconds
27. The method of claim 24, further comprising the step of notifying an operator of the system if a feedback loop failure occurs.
28. The method of claim 27, further comprising the steps of:
suspending the transmission of electric power from the generator;
commencing a resonance search and an output calculation mode;
monitoring the output for a minimum tolerance; and
restarting the feedback loop and resuming normal operation when the output surpasses the minimum tolerance.
29. An ultrasound therapeutic treatment system, comprising:
an ultrasound treatment device having
a generator capable of generating an ultrasound output;
an input device adapted to receive histological tissue data from a user including treatment tissue type and tissue depth;
a controller running treatment software to calculate an ultrasound dosage including a treatment duration value, an acoustic intensity value, and an output frequency value;
a plurality of ultrasonic transducer heads capable of receiving the ultrasound output from the generator to generate acoustic output; and
a cable having
a first end connector adapted to attach to the ultrasound treatment device;
and
a second end connector adapted to selectively attach to each of the plurality of ultrasonic transducer heads.
30. The system of claim 29, wherein each of the plurality of ultrasonic transducer heads includes at least one memory device capable of operable communication with the controller.
31. The system of claim 30, wherein the at least one memory device is adapted to operably communicate with the controller to communicate stored data to the controller for each of the plurality of ultrasonic transducer heads.
32. The system of claim 31, wherein the data stored at the at least one memory device is selectable from a group consisting of: temperature data, transducer head serial number, and calibration data.
33. The system of claim 29, wherein the attachment of the second end connector of the cable to each of the plurality of ultrasonic transducer heads results in a substantially watertight attachment.
34. The system of claim 29, wherein each of the plurality of ultrasonic transducer heads are configured to have different acoustic output capabilities.
35. An ultrasound therapeutic treatment system, comprising:
an ultrasound treatment device having
generator means for generating an ultrasound output;
input means for receiving histological tissue data from a user including treatment tissue type and tissue depth;
control means for running treatment software to calculate an ultrasound dosage including a treatment duration value, and an acoustic intensity value;
a plurality of delivery means for receiving the generated ultrasound output from the generator means to deliver acoustic output; and
means for communicating the generated ultrasound output to the delivery means, having
first connector means for attachment to the ultrasound treatment device;
and
second connector means for selective attachment to each of the plurality of delivery means.
36. The system of claim 35, wherein each of the plurality of delivery means includes storage means for storing data at the delivery means for communication with the control means.
37. The system of claim 35, wherein the plurality of delivery means are substantially watertight when attached to the second connector means.
38. The system of claim 35, wherein each of the plurality of delivery means are capable of having different acoustic output capabilities.
39. A method of interchangeably connecting a plurality of transducer treatment heads for use with an ultrasound therapeutic treatment device, the method comprising the steps of:
connecting a first transducer treatment head to a head connector at one end of a cable in operable communication with a generator of the ultrasound therapeutic treatment device;
disconnecting the first transducer treatment head from the head connector; and
connecting a second transducer treatment head to the head connector.
40. The method of claim 39, further including the step of reading, at a controller in operable communication with the cable, data stored at a memory device of the first transducer treatment head.
41. The method of claim 39, further including the step of reading, at a controller in operable communication with the cable, data stored at a memory device of the second transducer treatment head.
42. The method of claim 39, wherein the connecting of the second transducer head includes connecting the second transducer head having a different acoustic output capability than the first transducer treatment head.
43. A feedback loop for monitoring and controlling the acoustic power delivered at a treatment head of a therapeutic treatment system comprising:
at least one ultrasonic transducer capable of receiving an ultrasound output signal to generate an acoustic treatment output;
means for generating the ultrasound output signal in operable communication with the ultrasonic transducer;
means to supply a voltage control signal in operable communication with the means for generating the ultrasound output signal;
control means for running treatment software, wherein inputted histological tissue data is processed to calculate an ultrasound dosage including an acoustic intensity value and a treatment duration value, and wherein the controller is in operable communication with the means to supply a voltage control signal;
means to receive measured voltage and current signals and to supply a vector output signal in operable communication with the means for generating the ultrasound output signal and the control means;
means to provide reference signals in operable communication with the means to receive measured voltage and current signals and to supply a vector output signal; and
means to provide a reference wave in operable communication with the control means, with the means for generating the ultrasound electric output signal to provide a reference wave, and with the means to provide reference signals.
US11/066,102 2002-10-25 2005-02-25 Ultrasound therapeutic device Abandoned US20050203444A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/066,102 US20050203444A1 (en) 2002-10-25 2005-02-25 Ultrasound therapeutic device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/281,090 US6860852B2 (en) 2002-10-25 2002-10-25 Ultrasound therapeutic device
US11/066,102 US20050203444A1 (en) 2002-10-25 2005-02-25 Ultrasound therapeutic device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/281,090 Division US6860852B2 (en) 2002-10-25 2002-10-25 Ultrasound therapeutic device

Publications (1)

Publication Number Publication Date
US20050203444A1 true US20050203444A1 (en) 2005-09-15

Family

ID=32107100

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/281,090 Expired - Lifetime US6860852B2 (en) 2002-10-25 2002-10-25 Ultrasound therapeutic device
US11/066,102 Abandoned US20050203444A1 (en) 2002-10-25 2005-02-25 Ultrasound therapeutic device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/281,090 Expired - Lifetime US6860852B2 (en) 2002-10-25 2002-10-25 Ultrasound therapeutic device

Country Status (1)

Country Link
US (2) US6860852B2 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100425199C (en) * 2006-08-25 2008-10-15 北京源德生物医学工程有限公司 Extracorporeal high energy focusing ultrasonic system guided by permanent magnet type magnetic resonance image and method thereof
US20090082703A1 (en) * 2007-09-26 2009-03-26 Robert Muratore Method and apparatus for the treatment of tendon abnormalities
US20090326609A1 (en) * 2008-06-27 2009-12-31 Cardiac Pacemakers, Inc. Systems and methods of monitoring the acoustic coupling of medical devices
US20100241036A1 (en) * 2005-06-21 2010-09-23 Insightec, Ltd Controlled, non-linear focused ultrasound treatment
DE102009049795A1 (en) * 2009-10-16 2011-04-21 Reinhard Becker Ultrasonic treatment device and method for its operation
US8002706B2 (en) 2003-05-22 2011-08-23 Insightec Ltd. Acoustic beam forming in phased arrays including large numbers of transducer elements
US8078278B2 (en) 2006-01-10 2011-12-13 Remon Medical Technologies Ltd. Body attachable unit in wireless communication with implantable devices
US8088067B2 (en) 2002-12-23 2012-01-03 Insightec Ltd. Tissue aberration corrections in ultrasound therapy
US8235901B2 (en) 2006-04-26 2012-08-07 Insightec, Ltd. Focused ultrasound system with far field tail suppression
US8251908B2 (en) 2007-10-01 2012-08-28 Insightec Ltd. Motion compensated image-guided focused ultrasound therapy system
US8340776B2 (en) 2007-03-26 2012-12-25 Cardiac Pacemakers, Inc. Biased acoustic switch for implantable medical device
USRE43901E1 (en) 2000-11-28 2013-01-01 Insightec Ltd. Apparatus for controlling thermal dosing in a thermal treatment system
US8368401B2 (en) 2009-11-10 2013-02-05 Insightec Ltd. Techniques for correcting measurement artifacts in magnetic resonance thermometry
US8409099B2 (en) 2004-08-26 2013-04-02 Insightec Ltd. Focused ultrasound system for surrounding a body tissue mass and treatment method
US8425424B2 (en) 2008-11-19 2013-04-23 Inightee Ltd. Closed-loop clot lysis
US20130116538A1 (en) * 2011-11-02 2013-05-09 Seno Medical Instruments, Inc. Optoacoustic imaging systems and methods with enhanced safety
US8577460B2 (en) 2000-10-16 2013-11-05 Remon Medical Technologies, Ltd Acoustically powered implantable stimulating device
US8593107B2 (en) 2008-10-27 2013-11-26 Cardiac Pacemakers, Inc. Methods and systems for recharging an implanted device by delivering a section of a charging device adjacent the implanted device within a body
US8608672B2 (en) 2005-11-23 2013-12-17 Insightec Ltd. Hierarchical switching in ultra-high density ultrasound array
US8617073B2 (en) 2009-04-17 2013-12-31 Insightec Ltd. Focusing ultrasound into the brain through the skull by utilizing both longitudinal and shear waves
US8661873B2 (en) 2009-10-14 2014-03-04 Insightec Ltd. Mapping ultrasound transducers
US8932237B2 (en) 2010-04-28 2015-01-13 Insightec, Ltd. Efficient ultrasound focusing
WO2015080901A1 (en) * 2013-11-26 2015-06-04 Celleration Inc. Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing
US9177543B2 (en) 2009-08-26 2015-11-03 Insightec Ltd. Asymmetric ultrasound phased-array transducer for dynamic beam steering to ablate tissues in MRI
US9289154B2 (en) 2009-08-19 2016-03-22 Insightec Ltd. Techniques for temperature measurement and corrections in long-term magnetic resonance thermometry
US9623266B2 (en) 2009-08-04 2017-04-18 Insightec Ltd. Estimation of alignment parameters in magnetic-resonance-guided ultrasound focusing
US9713427B2 (en) 2006-09-15 2017-07-25 Cardiac Pacemakers, Inc. Mechanism for releasably engaging an implantable medical device for implantation
US9731141B2 (en) 2007-06-14 2017-08-15 Cardiac Pacemakers, Inc. Multi-element acoustic recharging system
US9852727B2 (en) 2010-04-28 2017-12-26 Insightec, Ltd. Multi-segment ultrasound transducers
US9981148B2 (en) 2010-10-22 2018-05-29 Insightec, Ltd. Adaptive active cooling during focused ultrasound treatment
US10321896B2 (en) 2011-10-12 2019-06-18 Seno Medical Instruments, Inc. System and method for mixed modality acoustic sampling
US10390714B2 (en) 2005-01-12 2019-08-27 Remon Medical Technologies, Ltd. Devices for fixing a sensor in a lumen
US10436705B2 (en) 2011-12-31 2019-10-08 Seno Medical Instruments, Inc. System and method for calibrating the light output of an optoacoustic probe

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6050943A (en) 1997-10-14 2000-04-18 Guided Therapy Systems, Inc. Imaging, therapy, and temperature monitoring ultrasonic system
US20100081893A1 (en) * 2008-09-19 2010-04-01 Physiosonics, Inc. Acoustic palpation using non-invasive ultrasound techniques to identify and localize tissue eliciting biological responses and target treatments
US20100087728A1 (en) * 2000-11-28 2010-04-08 Physiosonics, Inc. Acoustic palpation using non-invasive ultrasound techniques to identify and localize tissue eliciting biological responses
US20060079773A1 (en) * 2000-11-28 2006-04-13 Allez Physionix Limited Systems and methods for making non-invasive physiological assessments by detecting induced acoustic emissions
US7914453B2 (en) 2000-12-28 2011-03-29 Ardent Sound, Inc. Visual imaging system for ultrasonic probe
AU2002359576A1 (en) 2001-12-03 2003-06-17 Ekos Corporation Catheter with multiple ultrasound radiating members
US7857773B2 (en) * 2003-12-30 2010-12-28 Medicis Technologies Corporation Apparatus and methods for the destruction of adipose tissue
WO2005072409A2 (en) * 2004-01-29 2005-08-11 Ekos Corporation Method and apparatus for detecting vascular conditions with a catheter
US7393325B2 (en) 2004-09-16 2008-07-01 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment with a multi-directional transducer
US7824348B2 (en) 2004-09-16 2010-11-02 Guided Therapy Systems, L.L.C. System and method for variable depth ultrasound treatment
US9011336B2 (en) 2004-09-16 2015-04-21 Guided Therapy Systems, Llc Method and system for combined energy therapy profile
US8444562B2 (en) 2004-10-06 2013-05-21 Guided Therapy Systems, Llc System and method for treating muscle, tendon, ligament and cartilage tissue
US10864385B2 (en) 2004-09-24 2020-12-15 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US8535228B2 (en) * 2004-10-06 2013-09-17 Guided Therapy Systems, Llc Method and system for noninvasive face lifts and deep tissue tightening
US8133180B2 (en) 2004-10-06 2012-03-13 Guided Therapy Systems, L.L.C. Method and system for treating cellulite
US8690778B2 (en) 2004-10-06 2014-04-08 Guided Therapy Systems, Llc Energy-based tissue tightening
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US7758524B2 (en) 2004-10-06 2010-07-20 Guided Therapy Systems, L.L.C. Method and system for ultra-high frequency ultrasound treatment
US9827449B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
KR101605527B1 (en) 2004-10-06 2016-03-22 가이디드 테라피 시스템스, 엘.엘.씨. Ultrasound treatment system
EP1879502A2 (en) 2004-10-06 2008-01-23 Guided Therapy Systems, L.L.C. Method and system for cosmetic enhancement
US20060111744A1 (en) 2004-10-13 2006-05-25 Guided Therapy Systems, L.L.C. Method and system for treatment of sweat glands
US8663112B2 (en) 2004-10-06 2014-03-04 Guided Therapy Systems, Llc Methods and systems for fat reduction and/or cellulite treatment
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
JP4695188B2 (en) 2005-04-25 2011-06-08 アーデント サウンド, インコーポレイテッド Method and apparatus for improving the safety of computer peripherals
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US20070060988A1 (en) * 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US7981146B2 (en) * 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US20070016256A1 (en) * 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070088345A1 (en) * 2005-10-13 2007-04-19 Ust Inc. Applications of HIFU and chemotherapy
DE102005053918A1 (en) * 2005-11-11 2007-05-16 Zimmer Elektromedizin Gmbh Method and device for irradiating ultrasound in tissue
JP4921795B2 (en) * 2006-01-06 2012-04-25 株式会社東芝 Ultrasound drug introduction device and medical image diagnostic device
US20070239082A1 (en) * 2006-01-27 2007-10-11 General Patent, Llc Shock Wave Treatment Device
US7828734B2 (en) * 2006-03-09 2010-11-09 Slender Medical Ltd. Device for ultrasound monitored tissue treatment
US9107798B2 (en) 2006-03-09 2015-08-18 Slender Medical Ltd. Method and system for lipolysis and body contouring
US20090048514A1 (en) * 2006-03-09 2009-02-19 Slender Medical Ltd. Device for ultrasound monitored tissue treatment
US20070249938A1 (en) * 2006-04-20 2007-10-25 Donald J. Shields Systems, devices, and methods employing therapeutic ultrasound of living tissues
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8128673B2 (en) * 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) * 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7976573B2 (en) * 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981147B2 (en) * 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
WO2008027069A1 (en) * 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
US9566454B2 (en) 2006-09-18 2017-02-14 Guided Therapy Systems, Llc Method and sysem for non-ablative acne treatment and prevention
US20100041989A1 (en) * 2006-09-29 2010-02-18 The Trustees Of The University Of Pennsylvania Use of ultrasound as an antivascular agent
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
US20150174388A1 (en) 2007-05-07 2015-06-25 Guided Therapy Systems, Llc Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue
EP2152351B1 (en) 2007-05-07 2016-09-21 Guided Therapy Systems, L.L.C. Methods and systems for modulating medicants using acoustic energy
ES2699477T3 (en) 2007-05-07 2019-02-11 Guided Therapy Systems Llc Methods and systems for coupling and focusing acoustic energy using a coupling member
ES2471118T3 (en) 2007-06-22 2014-06-25 Ekos Corporation Method and apparatus for the treatment of intracranial hemorrhages
US8332071B2 (en) * 2007-08-20 2012-12-11 David Zeltzer System and method enabling sensorless actuator
US20100274161A1 (en) * 2007-10-15 2010-10-28 Slender Medical, Ltd. Implosion techniques for ultrasound
US8165668B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8195287B2 (en) * 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US20090149797A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System for reversible chemical modulation of neural activity
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8170660B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for thermal modulation of neural activity
US8160695B2 (en) * 2007-12-05 2012-04-17 The Invention Science Fund I, Llc System for chemical modulation of neural activity
US8165669B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8180446B2 (en) * 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
KR102147455B1 (en) 2008-06-06 2020-08-24 얼테라, 인크 Ultrasound treatment system
US7812504B1 (en) 2008-06-27 2010-10-12 Microtrend Systems Inc. Apparatus for high efficiency, high safety ultrasound power delivery with digital efficiency indicator and one clock cycle shutdown
CN105126262B (en) 2008-07-14 2019-03-22 代理并代表亚利桑那州立大学的亚利桑那董事会 Method and apparatus using ultrasound for adjusting cell activity
US20110178541A1 (en) * 2008-09-12 2011-07-21 Slender Medical, Ltd. Virtual ultrasonic scissors
US8303579B2 (en) * 2008-12-31 2012-11-06 Olympus Medical Systems Corp. Surgical operation system and surgical operation method
GB0916635D0 (en) * 2009-09-22 2009-11-04 Isis Innovation Ultrasound systems
GB0916634D0 (en) 2009-09-22 2009-11-04 Isis Innovation Ultrasound systems
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
AU2010315132A1 (en) * 2009-11-04 2012-05-31 Arizona Board Of Regents For And On Behalf Of Arizona State University Devices and methods for modulating brain activity
US8715186B2 (en) 2009-11-24 2014-05-06 Guided Therapy Systems, Llc Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy
US10369386B2 (en) 2010-05-27 2019-08-06 Koninklijke Philips N.V. Ultrasound transducer for selectively generating ultrasound waves and heat
US9504446B2 (en) 2010-08-02 2016-11-29 Guided Therapy Systems, Llc Systems and methods for coupling an ultrasound source to tissue
KR101939725B1 (en) 2010-08-02 2019-01-17 가이디드 테라피 시스템스, 엘.엘.씨. System and Method for Ultrasound Treatment
US8857438B2 (en) 2010-11-08 2014-10-14 Ulthera, Inc. Devices and methods for acoustic shielding
KR102068724B1 (en) 2011-07-10 2020-01-21 가이디드 테라피 시스템스, 엘.엘.씨. Systems and methods for improving an outside appearance of skin using ultrasound as an energy source
EP2731675B1 (en) 2011-07-11 2023-05-03 Guided Therapy Systems, L.L.C. Systems and methods for coupling an ultrasound source to tissue
EP2768385B1 (en) 2011-10-21 2021-03-31 Cerevast Medical, Inc. System for direct communication
KR101335607B1 (en) * 2012-01-09 2013-12-02 조소연 Ultrasonic transducer, electric pulse generator, and ultrasonic generation apparatus including the same
US9263663B2 (en) 2012-04-13 2016-02-16 Ardent Sound, Inc. Method of making thick film transducer arrays
BR112014029559B1 (en) * 2012-05-31 2022-04-12 Koninklijke Philips N.V. Ultrasonic transducer set and ultrasonic transducer head driving method
DE102012013534B3 (en) 2012-07-05 2013-09-19 Tobias Sokolowski Apparatus for repetitive nerve stimulation for the degradation of adipose tissue by means of inductive magnetic fields
US20140024975A1 (en) * 2012-07-17 2014-01-23 Liposonix, Inc. Hifu components with integrated calibration parameters
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
WO2014036170A1 (en) 2012-08-29 2014-03-06 Thync, Inc. Systems and devices for coupling ultrasound energy to a body
US9510802B2 (en) 2012-09-21 2016-12-06 Guided Therapy Systems, Llc Reflective ultrasound technology for dermatological treatments
CN104027893B (en) 2013-03-08 2021-08-31 奥赛拉公司 Apparatus and method for multi-focal ultrasound therapy
WO2014146022A2 (en) 2013-03-15 2014-09-18 Guided Therapy Systems Llc Ultrasound treatment device and methods of use
WO2014179356A1 (en) 2013-04-30 2014-11-06 Tear Film Innovations Llc Systems and methods for the treatment of eye conditions
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
EP3131630B1 (en) 2014-04-18 2023-11-29 Ulthera, Inc. Band transducer ultrasound therapy
US11491342B2 (en) 2015-07-01 2022-11-08 Btl Medical Solutions A.S. Magnetic stimulation methods and devices for therapeutic treatments
FR3035972B1 (en) * 2015-05-07 2017-04-28 Eye Tech Care METHOD FOR ADJUSTING OPERATING PARAMETERS FOR POWERING A TRANSDUCER
CN107708581B (en) 2015-06-10 2021-11-19 Ekos公司 Ultrasonic wave guide tube
US20180001107A1 (en) 2016-07-01 2018-01-04 Btl Holdings Limited Aesthetic method of biological structure treatment by magnetic field
US11266850B2 (en) 2015-07-01 2022-03-08 Btl Healthcare Technologies A.S. High power time varying magnetic field therapy
US10695575B1 (en) 2016-05-10 2020-06-30 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
US11253717B2 (en) 2015-10-29 2022-02-22 Btl Healthcare Technologies A.S. Aesthetic method of biological structure treatment by magnetic field
IL259944B (en) 2016-01-18 2022-07-01 Ulthera Inc Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof
US11247039B2 (en) 2016-05-03 2022-02-15 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
US11464993B2 (en) 2016-05-03 2022-10-11 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
US11534619B2 (en) 2016-05-10 2022-12-27 Btl Medical Solutions A.S. Aesthetic method of biological structure treatment by magnetic field
US10583287B2 (en) 2016-05-23 2020-03-10 Btl Medical Technologies S.R.O. Systems and methods for tissue treatment
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
US10556122B1 (en) 2016-07-01 2020-02-11 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
BR112018072101B1 (en) 2016-08-16 2024-01-02 Ulthera, Inc SYSTEMS AND METHODS FOR COSMETIC SKIN TREATMENT WITH ULTRASOUND
EP3721939B1 (en) 2019-04-11 2022-07-06 BTL Healthcare Technologies a.s. Device for aesthetic treatment of biological structures by radiofrequency and magnetic energy
US11878167B2 (en) 2020-05-04 2024-01-23 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
KR20230000081U (en) 2020-05-04 2023-01-10 비티엘 헬쓰케어 테크놀로지스 에이.에스. Device and method for unattended treatment of patients
US11896816B2 (en) 2021-11-03 2024-02-13 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
CN115475326A (en) * 2022-09-27 2022-12-16 重庆金山医疗技术研究院有限公司 Ultrasonic capsule
CN116520710B (en) * 2023-06-25 2023-09-15 智维精准(北京)医疗科技有限公司 Load-based drive control method and drive control system for accelerator

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368410A (en) * 1980-10-14 1983-01-11 Dynawave Corporation Ultrasound therapy device
US4614178A (en) * 1981-05-06 1986-09-30 Orvosi Muszerszovetkezet Automatic dose meter and control circuit arrangement
US4791915A (en) * 1986-09-29 1988-12-20 Dynawave Corporation Ultrasound therapy device
US4823775A (en) * 1984-09-14 1989-04-25 N.V. Verenigde Instrumentenfabrieken Enraf-Nonius Apparatus for treating a patient with ultrasonic waves
US4938217A (en) * 1988-06-21 1990-07-03 Massachusetts Institute Of Technology Electronically-controlled variable focus ultrasound hyperthermia system
US4966131A (en) * 1988-02-09 1990-10-30 Mettler Electronics Corp. Ultrasound power generating system with sampled-data frequency control
US5016615A (en) * 1990-02-20 1991-05-21 Riverside Research Institute Local application of medication with ultrasound
US5095890A (en) * 1988-02-09 1992-03-17 Mettler Electronics Corp. Method for sampled data frequency control of an ultrasound power generating system
US5184605A (en) * 1991-01-31 1993-02-09 Excel Tech Ltd. Therapeutic ultrasound generator with radiation dose control
US5267985A (en) * 1993-02-11 1993-12-07 Trancell, Inc. Drug delivery by multiple frequency phonophoresis
US5323769A (en) * 1990-02-23 1994-06-28 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
US5413550A (en) * 1993-07-21 1995-05-09 Pti, Inc. Ultrasound therapy system with automatic dose control
US5460595A (en) * 1993-06-01 1995-10-24 Dynatronics Laser Corporation Multi-frequency ultrasound therapy systems and methods
US5601526A (en) * 1991-12-20 1997-02-11 Technomed Medical Systems Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
US6055452A (en) * 1994-10-24 2000-04-25 Transcan Research & Development Co., Ltd. Tissue characterization based on impedance images and on impedance measurements
US6113559A (en) * 1997-12-29 2000-09-05 Klopotek; Peter J. Method and apparatus for therapeutic treatment of skin with ultrasound

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368410A (en) * 1980-10-14 1983-01-11 Dynawave Corporation Ultrasound therapy device
US4614178A (en) * 1981-05-06 1986-09-30 Orvosi Muszerszovetkezet Automatic dose meter and control circuit arrangement
US4823775A (en) * 1984-09-14 1989-04-25 N.V. Verenigde Instrumentenfabrieken Enraf-Nonius Apparatus for treating a patient with ultrasonic waves
US4791915A (en) * 1986-09-29 1988-12-20 Dynawave Corporation Ultrasound therapy device
US4966131A (en) * 1988-02-09 1990-10-30 Mettler Electronics Corp. Ultrasound power generating system with sampled-data frequency control
US5095890A (en) * 1988-02-09 1992-03-17 Mettler Electronics Corp. Method for sampled data frequency control of an ultrasound power generating system
US4938217A (en) * 1988-06-21 1990-07-03 Massachusetts Institute Of Technology Electronically-controlled variable focus ultrasound hyperthermia system
US5016615A (en) * 1990-02-20 1991-05-21 Riverside Research Institute Local application of medication with ultrasound
US5323769A (en) * 1990-02-23 1994-06-28 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
US5184605A (en) * 1991-01-31 1993-02-09 Excel Tech Ltd. Therapeutic ultrasound generator with radiation dose control
US5601526A (en) * 1991-12-20 1997-02-11 Technomed Medical Systems Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
US5267985A (en) * 1993-02-11 1993-12-07 Trancell, Inc. Drug delivery by multiple frequency phonophoresis
US5460595A (en) * 1993-06-01 1995-10-24 Dynatronics Laser Corporation Multi-frequency ultrasound therapy systems and methods
US5413550A (en) * 1993-07-21 1995-05-09 Pti, Inc. Ultrasound therapy system with automatic dose control
US6055452A (en) * 1994-10-24 2000-04-25 Transcan Research & Development Co., Ltd. Tissue characterization based on impedance images and on impedance measurements
US6113559A (en) * 1997-12-29 2000-09-05 Klopotek; Peter J. Method and apparatus for therapeutic treatment of skin with ultrasound

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8577460B2 (en) 2000-10-16 2013-11-05 Remon Medical Technologies, Ltd Acoustically powered implantable stimulating device
US8934972B2 (en) 2000-10-16 2015-01-13 Remon Medical Technologies, Ltd. Acoustically powered implantable stimulating device
USRE43901E1 (en) 2000-11-28 2013-01-01 Insightec Ltd. Apparatus for controlling thermal dosing in a thermal treatment system
US8088067B2 (en) 2002-12-23 2012-01-03 Insightec Ltd. Tissue aberration corrections in ultrasound therapy
US8002706B2 (en) 2003-05-22 2011-08-23 Insightec Ltd. Acoustic beam forming in phased arrays including large numbers of transducer elements
US8409099B2 (en) 2004-08-26 2013-04-02 Insightec Ltd. Focused ultrasound system for surrounding a body tissue mass and treatment method
US10390714B2 (en) 2005-01-12 2019-08-27 Remon Medical Technologies, Ltd. Devices for fixing a sensor in a lumen
US20100241036A1 (en) * 2005-06-21 2010-09-23 Insightec, Ltd Controlled, non-linear focused ultrasound treatment
US10130828B2 (en) * 2005-06-21 2018-11-20 Insightec Ltd. Controlled, non-linear focused ultrasound treatment
US8608672B2 (en) 2005-11-23 2013-12-17 Insightec Ltd. Hierarchical switching in ultra-high density ultrasound array
US8078278B2 (en) 2006-01-10 2011-12-13 Remon Medical Technologies Ltd. Body attachable unit in wireless communication with implantable devices
US8235901B2 (en) 2006-04-26 2012-08-07 Insightec, Ltd. Focused ultrasound system with far field tail suppression
CN100425199C (en) * 2006-08-25 2008-10-15 北京源德生物医学工程有限公司 Extracorporeal high energy focusing ultrasonic system guided by permanent magnet type magnetic resonance image and method thereof
US9713427B2 (en) 2006-09-15 2017-07-25 Cardiac Pacemakers, Inc. Mechanism for releasably engaging an implantable medical device for implantation
US8340776B2 (en) 2007-03-26 2012-12-25 Cardiac Pacemakers, Inc. Biased acoustic switch for implantable medical device
US9731141B2 (en) 2007-06-14 2017-08-15 Cardiac Pacemakers, Inc. Multi-element acoustic recharging system
US20090082703A1 (en) * 2007-09-26 2009-03-26 Robert Muratore Method and apparatus for the treatment of tendon abnormalities
US8548561B2 (en) 2007-10-01 2013-10-01 Insightec Ltd. Motion compensated image-guided focused ultrasound therapy system
US8251908B2 (en) 2007-10-01 2012-08-28 Insightec Ltd. Motion compensated image-guided focused ultrasound therapy system
US20090326609A1 (en) * 2008-06-27 2009-12-31 Cardiac Pacemakers, Inc. Systems and methods of monitoring the acoustic coupling of medical devices
US8798761B2 (en) * 2008-06-27 2014-08-05 Cardiac Pacemakers, Inc. Systems and methods of monitoring the acoustic coupling of medical devices
US8593107B2 (en) 2008-10-27 2013-11-26 Cardiac Pacemakers, Inc. Methods and systems for recharging an implanted device by delivering a section of a charging device adjacent the implanted device within a body
US9024582B2 (en) 2008-10-27 2015-05-05 Cardiac Pacemakers, Inc. Methods and systems for recharging an implanted device by delivering a section of a charging device adjacent the implanted device within a body
US8425424B2 (en) 2008-11-19 2013-04-23 Inightee Ltd. Closed-loop clot lysis
US8617073B2 (en) 2009-04-17 2013-12-31 Insightec Ltd. Focusing ultrasound into the brain through the skull by utilizing both longitudinal and shear waves
US9623266B2 (en) 2009-08-04 2017-04-18 Insightec Ltd. Estimation of alignment parameters in magnetic-resonance-guided ultrasound focusing
US9289154B2 (en) 2009-08-19 2016-03-22 Insightec Ltd. Techniques for temperature measurement and corrections in long-term magnetic resonance thermometry
US9177543B2 (en) 2009-08-26 2015-11-03 Insightec Ltd. Asymmetric ultrasound phased-array transducer for dynamic beam steering to ablate tissues in MRI
US8661873B2 (en) 2009-10-14 2014-03-04 Insightec Ltd. Mapping ultrasound transducers
US9412357B2 (en) 2009-10-14 2016-08-09 Insightec Ltd. Mapping ultrasound transducers
DE102009049795A1 (en) * 2009-10-16 2011-04-21 Reinhard Becker Ultrasonic treatment device and method for its operation
US8368401B2 (en) 2009-11-10 2013-02-05 Insightec Ltd. Techniques for correcting measurement artifacts in magnetic resonance thermometry
US9541621B2 (en) 2009-11-10 2017-01-10 Insightec, Ltd. Techniques for correcting measurement artifacts in magnetic resonance thermometry
US8932237B2 (en) 2010-04-28 2015-01-13 Insightec, Ltd. Efficient ultrasound focusing
US9852727B2 (en) 2010-04-28 2017-12-26 Insightec, Ltd. Multi-segment ultrasound transducers
US9981148B2 (en) 2010-10-22 2018-05-29 Insightec, Ltd. Adaptive active cooling during focused ultrasound treatment
US10321896B2 (en) 2011-10-12 2019-06-18 Seno Medical Instruments, Inc. System and method for mixed modality acoustic sampling
US10349921B2 (en) 2011-10-12 2019-07-16 Seno Medical Instruments, Inc. System and method for mixed modality acoustic sampling
US20150297090A1 (en) * 2011-11-02 2015-10-22 Seno Medical Instruments, Inc. Optoacoustic imaging systems and methods with enhanced safety
US20130116538A1 (en) * 2011-11-02 2013-05-09 Seno Medical Instruments, Inc. Optoacoustic imaging systems and methods with enhanced safety
US11633109B2 (en) 2011-11-02 2023-04-25 Seno Medical Instruments, Inc. Optoacoustic imaging systems and methods with enhanced safety
US10436705B2 (en) 2011-12-31 2019-10-08 Seno Medical Instruments, Inc. System and method for calibrating the light output of an optoacoustic probe
WO2015080901A1 (en) * 2013-11-26 2015-06-04 Celleration Inc. Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing
US11224767B2 (en) 2013-11-26 2022-01-18 Sanuwave Health, Inc. Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing
US11331520B2 (en) 2013-11-26 2022-05-17 Sanuwave Health, Inc. Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing

Also Published As

Publication number Publication date
US6860852B2 (en) 2005-03-01
US20040082857A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
US6860852B2 (en) Ultrasound therapeutic device
US20210322792A1 (en) Methods and Systems for Controlling Acoustic Energy Deposition Into A Medium
US10245449B2 (en) Systems and methods for coupling an ultrasound source to tissue
US9526477B2 (en) Systems and methods for monitoring and controlling ultrasound power output and stability
US5413550A (en) Ultrasound therapy system with automatic dose control
US10124187B2 (en) Combination of radiofrequency and magnetic treatment methods
JP5453259B2 (en) Ultrasound tissue treatment method and apparatus
US7828734B2 (en) Device for ultrasound monitored tissue treatment
US7955281B2 (en) External ultrasound lipoplasty
US6626854B2 (en) Systems and methods for ultrasound assisted lipolysis
US6511444B2 (en) Transmyocardial revascularization using ultrasound
US20060030798A1 (en) Method for therapeutic action with a ultrasonic field to biological tissues and a device for this purpose
US9931523B2 (en) RF power controller for ultrasound therapy system
US20150119763A1 (en) Methods and systems for non-invasive treatment of tissue using high intensity focused ultrasound therapy
US20050240170A1 (en) Insertable ultrasound probes, systems, and methods for thermal therapy
US20060265034A1 (en) Microwave devices for treating biological samples and tissue and methods for using same
US20050240239A1 (en) Method and system for gastric ablation and gastric pacing to provide therapy for obesity, motility disorders, or to induce weight loss
US20100042018A1 (en) Device for treating cellulite and fatty masses
WO2004100811A1 (en) Ultrasonic treatment equipment
KR101633707B1 (en) Radio frequency therapy apparatus and control method for radio frequency therapy apparatus
KR101607299B1 (en) Hyperthermia medical apparatus using high frequency electromagnetic wave
KR20180061105A (en) Ultrasonic transducer
US20090105617A1 (en) Non-invasive quantitative body contouring by high intensive focused ultrasound
JPH07108048A (en) Ultrasonic thermotherapeutic device

Legal Events

Date Code Title Description
AS Assignment

Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, MASSAC

Free format text: SECURITY AGREEMENT;ASSIGNORS:ENCORE MEDICAL HOLDINGS LLC;ENCORE MEDICAL FINANCE LLC;REEL/FRAME:018645/0158

Effective date: 20061103

AS Assignment

Owner name: ENCORE MEDICAL ASSET CORPORATION, NEVADA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:020196/0948

Effective date: 20071116

AS Assignment

Owner name: COMPEX MEDICAL S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHONENBERGER, KLAUS;BUHLMANN, FELIX;MULLER, PIERRE-YVES;AND OTHERS;REEL/FRAME:023479/0554

Effective date: 20021218

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION